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Preface 7 
1 Preface 
“What we know is a drop, what we don`t know is an ocean”. This is a quote by the English 
mathematician and physicist Sir Isaac Newton, one of the foremost scientists and a key player 
in the scientific revolution [1]. Almost 300 years later, substantial and constant progress has 
been made in virtually all fields of science to further broaden human knowledge and 
simultaneously reduce this “ocean” of ignorance. These fields of science also include the 
research on retinal disorders. Inherited retinal dystrophies (IRDs) are a major genetic cause of 
irreversible vision loss worldwide. Great advances have been made over the last decades in 
identifying genes and genetic defects leading to IRDs [2]. The peripherin-2 gene (PRPH2) was 
one of the first found to be associated with this disease [3]. Thereupon, constant research has 
been conducted to understand the precise function of peripherin-2, to identify additional 
disease-causing mutations in this gene, and to analyze their deleterious effects. However, 
despite great advances, many important questions concerning the pathophysiology of PRPH2 
mutations remained unclear, hampering the development of appropriate treatment strategies 
for the affected individuals. This PhD thesis was conducted to elucidate the disease 
mechanisms of enigmatic disease-linked peripherin-2 mutations. The results of this study 
gained unexpected and novel insights into the pathophysiology associated with this gene and 
may pave the way for future therapeutic interventions. 
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2 Introduction 
2.1 Anatomy of the retina 
The mammalian retina forms a thin sheet of neural tissue at the back of the eye. The 
fundamental, inverse organization of the retina is conserved across all vertebrates. The retina 
is composed of different neuronal and non-neuronal cell types. The five major neuronal cell 
types include the photoreceptors, bipolar cells, horizontal cells, amacrine cells and ganglion 
cells. The major non-neuronal retinal cell type are Müller glial cells, which provide metabolic 
and homeostatic support (Figure 1) [4]. Photoreceptors consist of rods and cones and convert 
the light into electrical signals, a process known as phototransduction. The photoreceptors are 
distally embedded in the retinal pigment epithelium (RPE) which is involved in phagocytosis of 
toxic products, in digestion of shed photoreceptor outer segments and in the regeneration of 
the visual pigment. The cell bodies of rods and cones form the outer nuclear layer (ONL) which 
is followed by the outer plexiform layer (OPL). In the OPL, electrical impulses generated in the 
photoreceptors are transmitted via synaptic connections to bipolar and horizontal cells [5]. 
Their cell bodies together with amacrine cells form the inner nuclear layer (INL). Proximal to 
the INL, bipolar and amacrine cells are connected to ganglion cells arranging the inner 
plexiform layer (IPL). Ganglion cells, shaping the ganglion cell layer (GCL), constitute the sole 
output neurons of the retina projecting their axons to higher visual centers in the brain [4]. 
 
 
Figure 1 Cellular structure of the retina [5]. 
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2.2 Anatomy of photoreceptors 
Rods and cones are the primary light-sensing cells of the retina. Rods account for 95 % of the 
photoreceptors in the human retina [3]. They are highly sensitive to light as they can detect 
even a single photon. Due to this remarkable feature, rods are ideally suited for  
dim-light and night vision constituting the scotopic pathway [6, 7]. In contrast, cones are 100 
times less sensitive than rods. However, they show much faster response kinetics during 
phototransduction. Depending on the species, different cone photoreceptor types can be found 
with each of them being most sensitive to light of a specific wavelength. Hence, cones are 
responsible for bright-light and color vision forming the photopic pathway [4]. Additionally, in 
primates they are highly concentrated in a specific region of the retina, termed macula, which 
mediates central high acuity vision [3].  
Rods and cones share a very similar basic morphology. Both photoreceptor types consist of 
an outer segment (OS), an inner segment (IS), the cell body containing the nucleus, and the 
axon terminating in the synapse. In rods, the OS harbors tightly stacked, individualized discs 
that are largely disconnected from the ciliary plasma membrane. In contrast, cones do not 
possess distinctly separated discs, but lamellae formed by evaginations of the cell membrane 
[8]. The next compartment, the IS, contains the cell machinery required for protein synthesis 
and energy production. It is linked to the OS via a connecting cilium tightly regulating the 
transport of cargo between both segments. The IS is followed by the nucleus and the axon 
which finally terminates in the synapse transmitting the electrical signal generated during 
phototransduction to downstream neurons.  
 
 
Figure 2 Rod and cone photoreceptor structure. Both cell types can be divided into three compartments: OS, 
IS, and the synaptic ending. OS and IS are coupled via the connecting cilium. Rod OSs contain discs, while cones 
have lamellae. 
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2.3 Inherited retinal diseases 
Inherited retinal diseases (IRDs) are a large group of genetically and clinically heterogeneous 
disorders affecting more than two million people worldwide [9]. They are inherited as Mendelian 
traits or via mitochondrial DNA, and are a major cause of gradual vision loss characterized by 
a slow and progressive degeneration of the retina, ultimately resulting in blindness. IRDs can 
either affect the entire retina or can be restricted to the macula. 
Cutting-edge treatment approaches including cell transplantation of retinal or stem cells, 
artificial retinal prostheses, and gene therapy have been researched through preclinical and 
clinical studies and have yielded significant progress during the recent decade [10]. On 
December 19, 2017, the first gene therapy treatment Voretigene Neparvovec (Luxturna, Spark 
Therapeutics) for Leber congenital amaurosis or retinitis pigmentosa, both IRDs, caused by a 
biallelic RPE65 mutation, was approved for clinical commercial use in the United States [11]. 
However, there are still many challenges to overcome, as the heterogeneity of causative genes 
in IRDs precludes the development of a common, gene- or mutation-independent treatment 
[10]. 
 
2.3.1 Retinitis pigmentosa 
Retinitis pigmentosa (RP) is the most common type of IRDs with an estimated incidence of 
1:3500 to 1:4000 [12]. Despite the diverse genetic origin with more than 3000 mutations in 
approx. 70 genes, RP patients share many clinical hallmarks. These include an abnormal, 
punctuate pigmentation and thinning of the retina due to dysfunction and degeneration of the 
photoreceptors and, in some cases, the RPE [10]. In the majority of RP cases, an initial 
degeneration of rods is followed by a secondary atrophy of cones. The deterioration of cones 
in the advanced stages of the disease is due to the co-dependence between the two 
photoreceptor types [13, 14]. In addition to night blindness, patients suffering from RP display 
a gradual loss of the peripheral visual field leading to tunnel vision. In the later stage, when 
cones start to degenerate, patients also show daylight vision impairments resulting from the 
loss of both peripheral and central vision [10]. 
All forms of RP are progressive, however, the mode of inheritance as well as the age of disease 
onset ranging from childhood to middle age are highly variable. RP can be inherited in an 
autosomal dominant, autosomal recessive, X-linked, or in rare cases also digenic manner [15, 
16]. To date, mutations in 22 different genes have been associated with autosomal dominant 
RP (adRP) [17]. However, only a few of these genes, including PRPH2, show a high 
prevalence in the populations examined so far [10].  
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2.4 Peripherin-2 
Peripherin-2, also known as retinal degeneration slow (RDS), is a photoreceptor-specific 
transmembrane glycoprotein which is crucial for the formation, maintenance and renewal of 
both rod and cone OSs [8, 18]. Accordingly, peripherin-2 knock out mice (rds-/-) are lacking 
OSs and show strong impairments of retinal function [19, 20]. In the OSs, peripherin-2 is 
exclusively located at the rim regions of the rod discs and cone lamellae [8, 21].  
The protein is encoded by the human peripherin-2 gene (PRPH2), which is localized on 
chromosome 6p21.2 and spans approx. 26 kb. PRPH2 consists of three exons segregated by 
two large introns [22]. Peripherin-2 belongs to the super-family of tetraspanins, which share 
several highly conserved structural features such as four helical transmembrane domains  
(T1-T4), a cytoplasmic N- and C-terminus and two extracellular (cones) or intradiscal (rods) 
loops termed D1 and D2 (Figure 3) [23, 24]. Generally, tetraspanins are known to form 
functional membrane microdomains assembling via homo- and heteromeric protein-protein 
interactions [25]. Peripherin-2 forms high-order oligomers composed of dimers tethered to non-
covalently linked tetramers. The tetramer formation is mediated by the large D2 loop [26, 27]. 
This tetrameric structure constituting the core unit of peripherin-2 is postulated to be crucial for 
proper trafficking to and incorporation into newly shaped rod OS disc membranes [28]. The D2 
loop contains seven cysteine residues, of which six (C165, C166, C213, C214, C222 and 
C250) are stabilizing its structure via intramolecular disulfide bonds [25, 29]. The remaining 
cysteine (C150) is involved in intermolecular disulfide bonding. By forming this disulfide bond 
the assembly of peripherin-2 tetramers into covalently linked octamers and higher-order 
complexes is initiated. The high-order oligomerization of peripherin-2 tetramers occurs in OSs 
and is essential for the correct formation of this compartment [29-33].  
 
 
Figure 3 Topology of peripherin-2. Peripherin-2 consists of four transmembrane domains (T1-T4). N- and  
C-terminus are cytoplasmic whereas the D1 and D2 loop are located within the extracellular space (in cones) or 
within the discs (in rods). 
Introduction 12 
2.5 Rom-1 
Rom-1 (rod outer segment membrane protein 1) is a non-glycosylated homolog of  
peripherin-2. Akin to peripherin-2, Rom-1 is localized to the rim regions of both rod and cone 
OSs [34, 35]. Both proteins share an approx. 35 % sequence identity and are forming  
non-covalently linked heterotetramers and covalently linked higher-order complexes [26, 34]. 
However, despite the aforementioned similarities, Rom-1 cannot compensate for the function 
of peripherin-2 [19, 20]. The precise function of Rom-1 has not been clarified yet, but previous 
studies suggest that it likely regulates OS morphogenesis by fine tuning the peripherin-2/Rom-
1 ratio and the distribution of peripherin-2 complexes to the rim regions of rod discs or cone 
lamellae [36].  
 
2.6 Mutations in PRPH2 and ROM1 
Over 150 individual disease-causing mutations in PRPH2 have been described in patients 
leading to a variety of clinical phenotypes. These are ranging from rod-dominant retinal 
disorders involving the peripheral retina such as RP or cone-rod dystrophy to multiple classes 
of cone-dominant macular dystrophies such as adult-onset foveomacular vitelliform dystrophy 
(AFVD), cone dystrophy and pattern dystrophy [22, 31, 37]. However, despite some progress 
in the past, the molecular mechanisms underpinning the differential penetrance of single 
PRPH2 mutations in rods and cones are largely unknown. This is due to the fact that rod- or 
cone-dominant mutations do not correlate with the type or position of the mutation in the 
primary protein sequence [38]. 
Most of the PRPH2 mutations have been implicated in adRP accounting for up to 10 % of all 
adRP cases: The majority of them are point mutations located in exon 2 [22, 39], which 
encodes for the distal half of the D2 loop domain and the proximal part of T4 (Figure 4).  
In contrast to PRPH2, no monogenic disease-causing mutations have been found in ROM1 so 
far [40]. However, a digenic form of RP has been associated with mutations in both PRPH2 
and ROM1 [41]. The affected persons are double heterozygous for the L185P mutation in 
PRPH2 and one of three different mutations in ROM1 [41-43]. Although the causal 
mechanisms of this rare digenic form of RP are yet not fully understood, previous studies 
propose abnormalities in peripherin-2/Rom-1 subunit assembly and/or reduced total levels of 
peripherin-2 and Rom-1 [44, 45]. 
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Figure 4 Disease-associated point mutations in peripherin-2 encoded by exon 2. The dashed box marks the 
exon 2-coding region comprising the distal half of the D2 loop and the proximal part of T4. Within the schematic 
magnification of this region (amino acids 195-276), positions of known disease-causing missense mutations are 
highlighted in red. 
 
2.7 Adeno-associated viruses 
Adeno-associated viruses (AAVs) belong to the Parvovirus family, more precisely the genus 
Dependovirus, and therefore can only replicate in the presence of adeno-, herpes-, or 
papilloma-viruses [46, 47]. AAVs are non-enveloped viruses with an icosahedral capsid 
packaging an approx. 4.7 kb linear single-stranded DNA genome and are among the smallest 
(approx. 25 nm) viruses known [46]. The wild type AAV genome is structurally characterized 
by inverted terminal repeats (ITRs) that flank the two open reading frames rep and cap. The 
ITRs are 145 bp palindromic sequences that form hairpin structures serving as origin of 
replication and facilitate genome packaging. The rep gene encodes four regulatory proteins 
crucial for DNA replication (Rep40, Rep52, Rep68, and Rep78), while cap encodes three 
structural proteins (VP1, VP2, and VP3) required for capsid formation. Due to their small 
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genome, AAVs can be easily manipulated by replacing viral rep and cap with a desired gene 
expression cassette thus making them a valuable multifunctional tool for different approaches 
in research including gene therapy [46, 47]. These recombinant adeno-associated virus (rAAV) 
vectors vary in their transduction efficiency and tropism, i.e. their preference for entering cells 
of a particular tissue, which is determined by their different serotypes. Among 12 human 
serotypes discovered to date, i.e. AAV1-12, AAV2 was the first serotype successfully applied 
in retinal gene transfer transducing the RPE and ganglion cells [46, 47]. Pseudotyping of 
rAAVs, i.e. the cross packaging of the genome of one ITR serotype into the capsid of a different 
serotype, has allowed broadening their tropism by creating novel hybrid vectors [48]. Thus, 
AAV2/8 containing the ITRs of AAV2 pseudotyped with the capsid of AAV8 has been shown 
to transduce murine photoreceptors very efficiently [49]. Rational design and directed evolution 
strategies led to the development of new AAV variants (e.g. AAV2/8Y33F or 7m8 AAV2) with 
improved transduction efficacies and/or widespread and faster transgene expression kinetics 
in retinal cells [50-52]. 
In conclusion, given the aforementioned properties and additional advantages of the rAAV 
vectors including the ability to infect both dividing and non-dividing cells, the lack of apparent 
pathogenicity, and episomal long-term expression, rAAV-mediated gene delivery is currently 
the most widely used approach for gene therapy in the retina [52-55]. 
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3 Aim of the study 
Point mutations in PRPH2 are associated with severe retinal dystrophies deteriorating the 
structure or function of rod or cone photoreceptors. The molecular pathways underlying this 
differential penetrance of individual PRPH2 mutants in rods and cones are currently unknown. 
However, the exact knowledge of these mechanisms is essential to develop appropriate 
treatment strategies for the affected individuals. 
 
The initial hypothesis of this study is that the rod- or cone-dominance of disease-linked PRPH2 
mutants might correlate with their differential effects on distinct molecular mechanisms in rods 
and cones. In particular, these mechanisms include i) mRNA splicing, ii) protein expression, 
iii) protein transport/localization, and iv) protein-protein interactions. To address this 
hypothesis, this study is set out to examine six rod- and five cone-dominant point mutations in 
PRPH2 in HEK293T cells and transduced murine photoreceptors. To achieve this goal, a 
variety of different methods will be applied. PRPH2 wild type and mutant minigenes will be 
used in all experiments for a comprehensive analysis of mRNA splicing and protein expression 
in vitro and in vivo. For the latter, recombinant adeno-associated virus (rAAV) vectors will be 
produced and subretinally delivered into wild type mice. Analysis of the protein-protein 
interactions will be achieved using FRET measurements and sucrose density gradient 
centrifugation.  
 
The results of this study will provide novel insights into the pathophysiology of PRPH2 
mutations and may offer new and innovative approaches for future therapies. 
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4 Materials and methods 
3.1 Animals 
For all experiments in this study, wild type C57Bl/6J mice were used. All procedures 
concerning animals were carried out with permission of local authorities (District Government 
of Upper Bavaria). Anesthesia was performed by intraperitoneal injection of ketamine  
(40 mg/kg body weight) and xylazine (20 mg/kg body weight). All mice received food  
(Ssniff; regular feed: R/M-H; breeding feed: M-Z Extrudat) and water ad libitum and were 
maintained in a 12 h light/dark cycle (lights on at 7 am). Euthanasia was performed by cervical 
dislocation. 
 
3.2 Chemicals, solutions and buffers 
All chemicals used had the quality “pro analysi” or “for molecular biological use” and were 
obtained from VWR, Sigma-Aldrich, Merck, Fluka, Roche, Bio-Rad or Roth if not mentioned 
otherwise. For all solutions, high pure and deionized water was used (Milli-Q Plus System, 
Millipore). Additionally, all solutions and buffers were autoclaved (Sterilisator, Münchener 
Medizin Mechanik). 
 
3.3 Molecular biology 
3.3.1 Plasmids 
 
pcDNA3.1 
The standard pcDNA3.1 vector (Invitrogen) was designed for high-level stable and transient 
expression in mammalian cell lines. In this study, it was used for the transient transfection of 
transgenes in SV40 large T antigen expressing HEK293T cells (LentiX 293 T Cell Line, 
Clontech Laboratories). 
 
pAAV2.1 
For episomal in vivo expression of transgenes delivered by recombinant adeno-associated 
viruses (rAAVs), the pAAV2.1 cis [52, 53] plasmid was used. The DNA packaging capacity of 
rAAVs comprises approx. 4.7 kb including the inverted terminal repeats (ITRs), the coding 
sequence of the gene of interest and regulatory elements, such as promoter or transcriptional 
termination sequences [56, 57]. In this study, the vector contained the human rhodopsin 
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promoter (hRHO) [58] or murine short-wavelength opsin promoter (mSws) [53] for specific 
gene expression in murine rod or cone photoreceptors. The expression cassette was flanked 
by AAV2 ITRs. The ITRs encode all cis-acting elements for efficient replication (rep) and 
packaging (cap) of rAAVs in the presence of an additional AAV trans and adenovirus helper 
plasmid (pAD Helper). As AAV trans plasmid pAAV2/8YF [59] was used containing the AAV2 
rep gene and capsid protein encoding genes from AAV8 for enhanced specific transduction of 
photoreceptors [58, 60, 61]. As adenovirus helper plasmid pAdDeltaF6 [62] was used. 
 
3.3.2 Polymerase chain reaction (PCR) 
PCR reaction conditions and pipetting schemes were adjusted for the different polymerases 
and the respective application according to the manual of the corresponding manufacturer. 
Standard PCR conditions of each polymerase are summarized in Table 1: 
Table 1 Standard PCR conditions for polymerases used in this study. 
Polymerase 
Q5 
(NEB) 
Kapa HiFi 
(Roche) 
Herculase II 
(Agilent Technologies) 
Initial denaturation 98 °C 30 sec 95 °C   3 min 95 °C   2 min 
Denaturation 98 °C 10 sec 98 °C 20 sec 95 °C 20 sec 
Annealing X °C 30 sec X °C 15 sec X °C 20 sec 
Elongation 72 °C 30 sec/kb 72 °C 30 sec/kb 72 °C 30 sec/kb 
Final elongation 72 °C   2 min 72 °C   1 min/kb 72 °C   3 min 
Hold 10 °C 15 min 10 °C 15 min 10 °C 15 min 
 
The annealing temperatures (X) were chosen with regard to the respective melting 
temperatures of the used primers purchased from Eurofins Genomics. The number of cycles 
used for denaturation, annealing and elongation was adjusted depending on the respective 
application. 
 
3.3.3 Precipitation of DNA fragments 
To purify a PCR product, H2O was added to a total volume of 100 µl followed by 10 µl of  
3 M sodium acetate buffer pH 5.2 and 275 µl of cold ethanol (100 %). The mixture was 
incubated at -80 °C for 10 minutes. Afterwards, the solution was centrifuged at 20.000 x g at 4 
°C for 15 minutes. The supernatant was discarded and the pellet was washed with 70 % (v/v) 
cold ethanol before centrifuging at 20.000 x g and 4 °C for another 5 minutes. The pellet was 
dried at 50 °C for 20 minutes before resuspension in an appropriate amount of H2O. 
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3.3.4 Restriction analysis 
All restriction enzymes (FastDigest) used in this work were purchased from Thermo Fisher 
Scientific. Restriction digest conditions were conducted according to the manufacturer’s 
instructions. The amount of DNA used for cloning applications was 3 µg. In contrast, 0.5 µg of 
isolated plasmid DNA were used for restriction analysis. 
 
3.3.5 Agarose gel electrophoresis and DNA fragment isolation 
To isolate or check for correct bands after restriction digest, the cut DNA was directly loaded 
on an appropriately concentrated agarose gel (peqGOLD Universal-Agarose, peqlab) 
containing peqGreen dye (peqlab) for visualization under UV light. GeneRuler 1 kb plus DNA 
ladder (Thermo Fisher Scientific) was used as DNA size reference. The DNA fragments were 
separated by size in 1x TBE buffer at 150 V. For cloning, desired DNA bands were excised 
from the gel and isolated using the QIAquick Gel Extraction Kit (Qiagen) according to the 
manufacturer’s protocol. 
1x TBE buffer 
0.5 M EDTA pH 8.0 20.0 ml 
Boric acid 27.5 g 
Tris 54.0 g 
H2O add to 5 l 
 
3.3.6 Dephosphorylation and ligation 
To prevent their re-ligation, vectors cut with a restriction enzyme generating blunt ends were 
dephosphorylated using the Rapid DNA Dephosphorylation Kit (Roche) according to the 
manufacturer’s instructions.  
For ligation, T4 DNA Ligase (Thermo Fisher Scientific) was utilized in accordance with the 
manufacturer’s manual. The vector to insert molar ratios ranged from 1:3 to 1:6. 
 
3.3.7 Transformation 
For transformation, a 100 µl aliquot of chemically competent cells (10-beta competent E. coli 
strain, NEB) was thawed on ice. 1-10 ng of plasmid DNA or 3-5 µl of a ligation mixture were 
added to the cell suspension which was then gently mixed and incubated on ice for 5-30 
minutes. After incubation, a heat shock at 42 °C for 30-45 seconds was performed.  
Heat-shocked cells were returned on ice for at least 2 minutes before plating them on LB(+) 
agar plates containing 100 µg/ml ampicillin (resistance depending on the plasmid). Afterwards, 
the plate was incubated overnight at 37 °C in an inverted position. 
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LB(+) medium  LB(+) agar  
Peptone 10 g  Agar 15 g 
Yeast extract 5 g  LB(+) medium add to 1 l 
NaCl  5 g  Autoclave  
D-(+)-Glucose 1 g   
H2O add to 1 l   Let the solution cool down to 50 °C and add 
Adjust pH to 7.2-7.5 and autoclave Ampicillin          100 mg    
 
3.3.8 Inoculation of bacterial cells and isolation of plasmid DNA 
Bacterial colonies were picked from the agar plate and transferred to culture tubes (Sarstedt) 
containing 5 ml LB(+) medium and ampicillin (100 µg/ml). The bacterial cultures were 
incubated overnight at 37 °C while shaking at 225 rpm. On the next day, the cells were 
centrifuged at 3500 rpm and room temperature (RT) for 10 minutes. After discarding the 
supernatant, the cell pellet was resuspended in 250 µl resuspension buffer and transferred to 
a 1.5 ml Eppendorf tube. 250 µl lysis buffer was added to the solution which was then mixed 
by inverting the tube 5-6 times followed by an incubation for 5 minutes at RT. 250 µl 
neutralization buffer was added and the mixture was inverted 5-6 times before incubating it 15 
minutes on ice. Then, the suspension was centrifuged at 20.000 x g and 4 °C for 15 minutes. 
The supernatant was transferred to a new 1.5 ml Eppendorf tube and 525 µl of cold isopropanol 
(100 %) was added to precipitate the DNA. After vortexing, the solution was centrifuged at 
20.000 x g and 4 °C for 15 minutes. The supernatant was removed and 700 µl 70 % (v/v) 
ethanol was added before centrifuging at 20.000 x g and 4 °C for 5 minutes. The supernatant 
was discarded and the pellet was dried at 50 °C for 20 minutes before resuspension in 20 µl 
H2O. DNA concentration and purity were determined using a Nanodrop 2000c 
spectrophotometer (Thermo Fisher Scientific).  
All constructs used in this study were sequenced at Eurofins Genomics prior to use. For large 
scale and high purity plasmid isolation the PureLink HiPure Plasmid Midiprep or Megaprep Kit 
(Invitrogen) was used. For this purpose, 100 ml or 1000 ml LB(+) medium was inoculated with 
single colonies according to the manufacturer’s instructions. 
 
Resuspension buffer  Lysis buffer 
Tris 6.06 g  NaOH 8.0 g 
EDTA 3.72 g  10 % (w/v) SDS solution 100 ml 
RNAse A 100 mg  H2O add to 1 l 
H2O add to 1 l    
Adjust pH to 8.0    
    
Neutralization buffer 
3 M potassium acetate pH 5.5 500 ml 
H2O add to 1 l 
Materials and methods 20 
3.3.9 RNA isolation and cDNA synthesis 
RNA isolation from murine or human tissue was conducted using the RNeasy Plus Minikit 
(Qiagen) according to the instructions of the manufacturer. RNA concentration and purity were 
determined using the Nanodrop 2000c spectrophotometer. Subsequent reverse transcription 
was performed using the RevertAid First Strand cDNA Synthesis Kit (Thermo Fisher Scientific) 
following the manual of the manufacturer. For cDNA synthesis from transfected cell culture 
experiments, the amount of total RNA was 500 ng. Random hexamers as well as oligo(dT) 
primers were added to the reaction. For cDNA synthesis from sorted murine rods and cones 
(cf. chapter 3.11), 50 ng of isolated total RNA was used.  
 
3.3.10 Quantitative real-time PCR (qPCR) 
qPCR was performed using the SYBR Select Master Mix (Applied Biosystems) on a 
StepOnePlus Real-Time PCR System (Applied Biosystems). Pipetting scheme and reaction 
conditions were adapted from the manufacturer’s manual and adjusted for every gene 
individually. Murine or human gene expression was normalized to the housekeeping gene 
aminolevulinic acid synthase (Alas/ALAS). Three technical replicates were run for each gene 
of interest. Relative quantification was performed according to the 2−ΔΔCT method [63]. All 
relevant primer sequences for detection of murine and human transcripts can be found in the 
appendix (cf. Supplementary Table 8). 
 
3.3.11 In silico prediction of splicing 
Prior to examining the effects of potential splice mutations via minigenes, an initial in silico 
prediction of mRNA splicing of the mutations of interest was conducted [64]. Therefore, the 
free trial ASSEDA splice software (splice.uwo.ca/) and the open access NNSplice software 
(Berkeley Drosophila Genome Project, http://www.fruitfly.org/seq_tools/splice.html) were 
used. For in silico prediction, 40 bp flanking the respective point mutation from each side were 
chosen. The software can predict different effects on mRNA splicing, e.g. the potential 
generation of novel donor or acceptor splice sites and the generation or abolition of exonic 
splice enhancer (ESE) or silencer (ESS) motifs. In this study, 30 PRPH2 point mutations were 
analyzed via this in silico approach (cf. Supplementary Table 1). 
 
3.3.12 Genomic DNA isolation 
Genomic DNA was extracted from buccal cells isolated from Dr. Elvir Becirovic using the 
Gentra Puregene Buccal Cell Kit (Qiagen) following the instructions of the manufacturer.  
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3.3.13 Construction and cloning of the PRPH2 minigene 
To generate the human PRPH2 minigene overlap extension PCR was used. The genomic 
DNA isolated from Dr. Elvir Becirovic served as template (cf. chapter 3.3.12). First, the three 
exons including ≥ 200 bp of the flanking introns were amplified via standard PCR (Figure 5). 
The primers used for these PCRs encompass defined overhangs of approx. 20 bp. These 
overhangs are complementary to the corresponding PCR amplicon to be connected in the 
subsequent overlap extension PCR. Thus, 40 bp overlap regions are created which were used 
for the amplification of two fragments. In addition, to amplify the first minigene exon, an 
appropriate restriction site was added to the 5’ end of the corresponding forward primer. For 
the amplification of the last exon, an appropriate restriction site was added to the 5’ end of the 
corresponding reverse primer. The two amplicons PCR1 and PCR2 served as templates for 
the first overlap PCR. This new fragment was fused in the second overlap PCR to the 
remaining amplicon PCR3 yielding the final PRPH2 minigene. Using the chosen restrictions 
sites, the minigene was cloned into the respective expression vector. A list of the used primers 
can be found in Supplementary Table 5. 
 
 
Figure 5 Schematic of overlap extension PCR for creating the human PRPH2 minigene consisting of three 
exons and two flanking introns that were shortened [64].  
For monitoring expression and performing FACS and FRET experiments, the fluorophores 
citrine or cerulean were fused to the 5’ end of the PRPH2 minigene. 
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3.3.14 Side-directed mutagenesis 
Point mutations were introduced into the PRPH2 minigene by side-directed mutagenesis using 
the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies) according to 
the manufacturer’s manual. Mutagenic oligonucleotide primers were designed using the 
QuikChange primer design program (www.agilent.com/genomics/qcpd) and purchased at 
Eurofins Genomics (cf. Supplementary Table 6). All mutant minigenes were sequenced prior 
to use. 
 
3.4 Cell culture 
3.4.1 Cultivation of mammalian cell lines 
HEK293T cells (LentiX 293 T Cell Line, Clontech Laboratories) were used for in vitro 
transfections in this study. The cells were cultivated in DMEM + GlutaMAXTM-I medium  
((+) 4.5 g/l glucose, (-) pyruvate, (+) 10 % FBS, (+) 1 % penicillin/streptomycin (Thermo Fisher 
Scientific)) at 37 °C and 10 % CO2. 
 
3.4.2 Transfection 
HEK293T cells were either transiently transfected using the calcium phosphate technique [65] 
or the polymer-based transfection reagent TurboFect (Thermo Fisher Scientific). For the 
calcium phosphate based transfection of a 10 cm dish (Cellstar, Greiner), the following 
reagents were premixed in a 15 ml Falcon tube: 
 
DNA 10 µg  2x BBS solution  
2.5 M CaCl2 50 µl  BES 10.65 g 
H2O add to 500 µl  NaCl 16.35 g 
   Na2HPO4 x 2H2O 0.21 g 
   H2O add to 1 l 
   Adjust pH to 6.95 and filtrate sterilely 
 
While vortexing, 500 µl of 2x BBS solution were added dropwise to the mixture. After incubating 
for 5 minutes at RT, the transfection mix was evenly distributed on approx. 70 % confluent 
cells. The cells were then incubated at 37 °C and 5 % CO2 for 8-16 hours before changing the 
medium and placing them back to 37 °C and 10 % CO2 until harvesting.  
TurboFect was used for the transfection of cells cultivated in glass bottomed 35 mm dishes 
(Cellvis) for subsequent FRET measurements. The required DNA and medium volumes were 
adjusted in accordance with the manufacturer’s protocol. After vortexing, the mixture was 
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incubated for 15-20 minutes at RT. Finally, it was spread on the cells and incubated at 37 °C 
until proceeding with the FRET measurements. 
 
3.5 Protein biochemistry 
3.5.1 Isolation and quantification of proteins 
Proteins were isolated 48 hours after transfection of HEK293T cells. Afterwards, the medium 
was removed and cells were scraped off the dish and collected in a 1.5 ml Eppendorf tube. 
Cells were then centrifuged at 1000 x g at 4 °C for 10 minutes. After removing the remaining 
medium, the pellet was resuspended in an appropriate amount of lysis buffer, disrupted using 
the Potter S homogenizer (B. Braun Diessel Biotech) and rotated at 4 °C for 20 minutes. 
Subsequently, the cells were centrifuged at 5000 x g and 4 °C for 10 minutes before 
transferring the supernatant into a new 1.5 ml tube. For protein isolation from mouse tissue a 
similar protocol was used.  
Total protein concentration was determined using the Bradford assay [66]. For this purpose,  
5 µl of protein lysate were mixed with 95 µl of 0.15 M NaCl solution and transferred to a 1 ml 
PMMA cuvette (Brand). 5 µl of lysis buffer served as blank control. 1 ml of Coomassie blue 
solution was added and incubated at RT for 2 minutes before measuring the concentration via 
a BioPhotometer (Eppendorf). 
 
Lysis buffer  Coomassie blue solution 
Triton X-100 2.5 ml  Coomassie brilliant blue G250 50 mg 
5 M NaCl 15 ml  95 % (v/v) ethanol 25 ml 
2.5 M CaCl2 0.4 ml  85 % (v/v) phosphoric acid 50 ml 
H2O add to 500 ml  H2O add to 500 ml 
 
3.5.2 Membrane preparations 
Membrane preparations were performed to enrich membrane proteins from transfected 
HEK293T cells or transduced murine retinas. For this purpose, harvested cells or tissue were 
lysed in an appropriate amount of 1x membrane preparation buffer containing a cOmplete 
EDTA-free Protease Inhibitor Cocktail (Roche) using the Potter S homogenizer. The solution 
was centrifuged at 5000 x g at 4 °C for 10 minutes before transferring the supernatant into a 
6.5 ml clean thick wall polycarbonate tube (16 x 64 mm, Beckman Coulter). 1x membrane 
preparation buffer was added to the tube to a final volume of 4 ml prior to centrifugation at 
30.000 rpm and 4 °C for 45 minutes in a Sorvall Discovery 90 ultracentrifuge using a 45 Ti 
rotor (Beckman Coulter). The supernatant was discarded and the pellet was resuspended in 
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50-100 µl of 1x membrane preparation buffer. 5 µl were used for protein quantification via the 
Bradford assay (cf. chapter 3.5.1). 
3x membrane preparation buffer 
MOPS 3.15 g 
Sucrose 77 g 
0.5 M EDTA pH 7.4 6 ml 
H2O add to 250 ml 
 
3.5.3 Co-immunoprecipitation (co-IP) 
To analyze protein-protein interactions via co-IP experiments protein G dynabeads (novex by 
Life Technologies) were used. 5 µg of an appropriate antibody was added to 30 µl of 
dynabeads. This mixture was filled up to a final volume of 500 µl with PBS. To allow a binding 
of the antibodies to the beads, the solution was rotated at 4 °C for 30 minutes. Afterwards, the 
fluid was removed from the beads by withholding them with a magnet. The beads were then 
washed in 200 µl PBS followed by adding 1 mg of the protein lysate (cf. chapter 3.5.1 or 3.5.2) 
and filling up the reaction to a final volume of 500 µl with PBS. While rotating, the solution was 
incubated for 30-60 minutes at 4 °C before washing the beads three times with 200 µl PBS. 
After the last washing step, the complete bead suspension was transferred to a new 1.5 ml 
Eppendorf tube and the fluid was discarded. Beads were resuspended in 10 µl PBS and 6x 
Lämmli buffer with or without DTT (depending on the application) was added. The suspension 
was incubated at 75 °C for 10 minutes to elute bound proteins from the bead-antibody 
complexes. The resulting protein-enriched solution was removed from the beads and loaded 
on a SDS-PAGE gel (cf. chapter 3.5.4). 
 
6x Lämmli buffer 
Tris-HCl pH 6.8 7 ml 
Glycerol 3 ml 
SDS 1.0 g 
Bromophenol blue 1.2 mg 
(DTT 0.93 g) 
H2O add to 10 ml 
 
3.5.4 SDS-PAGE 
To separate isolated proteins according to their molecular weight SDS-PAGE was used. For 
this, 6-12 % gradient gels were prepared using the Mini Protean 3 gel system (Bio-Rad). First, 
4.25 ml of a 6 % gel solution were aspirated using a 10 ml pipette followed by 4.25 ml of a 12 
% gel solution. The gradient was generated by carefully aspirating one air bubble prior to 
pouring the gel solution into the gel system.  
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As molecular weight standard PageRuler Prestained Protein Ladder (Thermo Fisher Scientific) 
was used. Electrophoresis was run in electrophoresis buffer at 140 V for 1 hour. 
 
1x Electrophoresis buffer 
Tris base 3.03 g 
Glycin 14.4 g 
SDS 1.0 g 
H2O add to 1 l 
 
4x Tris-HCl/SDS buffer 0.5 M  4x Tris-HCl/SDS buffer 1.5 M 
Tris base 0.5 M  Tris base 1.5 M 
SDS 0.4 %  SDS 0.4 % 
H2O add to 500 ml  H2O add to 500 ml 
Adjust pH to 6.8 with HCl   Adjust pH to 8.8 with HCl  
 
Stacking gel (for 2 gels) 
30 % acrylamide/bis-acrylamide 1 ml 
4x Tris-HCl/SDS buffer 0.5 M 1.9 ml 
H2O 4.6 ml 
APS 37.5 µl 
TEMED 7.5 µl 
 
 
Gradient separation gel (for 2 gels)      6 %    12 % 
30 % acrylamide/bis-acrylamide 2.3 ml 4.6 ml 
4x Tris-HCl/SDS buffer 1.5 M 2.8 ml 2.8 ml 
H2O 6.2 ml 3.9 ml 
APS 22.5 µl 22.5 µl 
TEMED 7.5 µl 7.5 µl 
 
3.5.5 Western blotting 
Following SDS-PAGE, separated proteins were blotted on a PVDF membrane (peqlab) 
equilibrated in methanol using the Mini Trans-Blot Cell (Bio-Rad). Western blotting was 
performed at 100 V for 90 minutes in transfer buffer. After blotting, the membrane was 
incubated in blocking solution for 1 hour at RT while rotating. The membrane was then 
incubated in the appropriate primary antibody solution for 1 hour at RT followed by 3 washing 
steps in TBST for 5 minutes. Afterwards, the membrane was transferred to the secondary 
antibody solution and incubated for 1 hour at RT while rotating. Subsequently, the membrane 
was washed 3 times in TBST and once in H2O prior to chemiluminescence detection via the 
Western Blotting Luminol Reagent (Santa Cruz) using the Chemidoc MP Imaging system  
(Bio-Rad) and the ImageLab software. A list of all antibodies used in this study can be found 
in Table 2. 
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Transfer buffer  TBST 
Tris 3.0 g  Tris 1.2 g 
Glycin 14.4 g  NaCl 8.0 g 
H2O add to 1 l  Tween 20 1 ml 
   H2O add to 1 l 
 
Blocking solution  Primary/secondary antibody solution 
TBST 15 ml  TBST 5 ml 
Non-fat dried milk powder 0.75 g  Non-fat dried milk powder 0.05 g 
   Antibody stock solution x µl 
   x: depending on the concentration 
 
Table 2 Antibodies used for western blotting. 
Antibody Source Dilution 
rb anti-CNGB1a in-lab production 1:5000 
ms anti-GFP JL-8 Clontech 1:2000 
ms anti-myc 9B11 Cell Signaling Technology 1:2000 
ms anti-Na+/K+ ATPase a6F-c Developmental Studies Hybridoma Banks, 
University of Iowa 
1:1000 
ms anti-ATPase alpha3 Abcam 1:2000 
rb anti-flag Sigma 1:2000 
gt anti-mouse HRP Santa Cruz 1:2000 
gt anti-rabbit HRP Santa Cruz 1:2000 
 
3.5.6 Native protease cleavage assay 
For the native protease cleavage assay, membrane preparations (cf. chapter 3.5.2) from 
transfected HEK293T cells were performed in absence of protease inhibitors. This membrane 
protein solution was incubated for 5 hours at RT to allow for endogenously expressed 
proteases to cleave exposed domain regions of the isolated proteins. Subsequently, they were 
further processed for western blotting (cf. chapter 3.5.5).  
 
3.5.7 Peptide competition assay 
The peripherin-2 peptide (sequence: DGRYLVDGVPFSCCNPSSPR) used for the peptide 
competition assay was purchased at jpt Innovative Peptide Solutions. It was added to the 
respective membrane preparations (cf. chapter 3.5.2) before starting with the co-IP 
experiments (cf. chapter 3.5.3) using an anti-myc antibody (cf. Table 2). 
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3.6 Sucrose density gradient centrifugation 
A sucrose density gradient centrifugation (SDGC) facilitates the separation of different 
covalently or non-covalently linked protein complexes across a sucrose gradient according to 
their specific molecular weight. For SDGC, HEK293T cells were transiently transfected  
(cf. 3.4.2) with the respective peripherin-2 and Rom-1 constructs. 48 hours post transfection, 
cells were harvested and processed as described in chapter 3.5.1. Continuous density 
gradients of 5-20 % (w/v) sucrose were prepared by underlayering 0.5 ml of 5 %, 10 %, 15 % 
and 20 % sucrose solutions containing 10 mM N-ethylmaleimide (Sigma-Aldrich) and 0.1 % 
Trition X-100 into a centrifuge tube (Beranek Laborgeräte). To allow for diffusion, the gradient 
was left at RT for 1 hour and chilled on ice for another 30 minutes prior to sample application. 
DNA standards of defined molecular weights (75-20.000 bp, i.e. 49-13.000 kDa, GeneRuler  
1 kb Plus (Thermo Fisher Scientific)) were added to lysates containing 200 µg of the respective 
proteins to be able to determine the weight of the single peripherin-2 and Rom-1 complexes in 
subsequent immunoblots. The mix was then carefully layered on top of the gradient and 
centrifuged at 46.700 rpm at 4 °C for 2 hours in a Beckman Coulter Optima L-80K 
Ultracentrifuge (Beckman Coulter). Hereafter, the centrifuge tube was punctured at the bottom 
and fractions were collected dropwise (5 drops/tube). Fractions from every sucrose gradient 
were used separately for western blotting (cf. chapter 3.5.5) utilizing anti-flag- or -myc-specific 
antibodies (cf. Table 2) and for agarose gel electrophoresis to detect the DNA standards.  
 
3.7 Production of rAAVs 
3.7.1 Transfection and harvest 
Single-stranded rAAVs were produced by triple calcium phosphate transfection of HEK293T 
cells (cf. chapter 3.4.2) with the pAAV2.1 vector containing the transgene as well as the pAD 
Helper and pAAV2/8YF plasmids (cf. chapter 3.3.1). To achieve higher transfection 
efficiencies, dextran 500 (Sigma) and polybrene (hexadimethrine bromide, Sigma) were mixed 
with the regular transfection compounds [67]. 15x 15 cm dishes of HEK293T cells were 
transfected to generate one batch of rAAVs according to the following reaction mixture: 
Transfection mixture 
pAAV2.1 vector 270 µg 
pAD Helper X µg 
pAAV2/8YF Y µg 
Polybrene (8 mg/ml) 15 µl 
Dextran (10 mg/ml) 1.5 ml 
2.5 M CaCl2 1.5 ml 
H2O add to 15 ml 
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The necessary amounts of pAD Helper and pAAV2/8YF plasmids were calculated as follows: 
 
X µg = 270 µg x MM of pAD Helper / MM of pAAV2.1 vector     (1) 
Y µg = 270 µg x MM of pAAV2/8YF / MM of pAAV2.1 vector    (2) 
 
MM = molar mass of double stranded plasmid 
MM of pAD Helper = 9509 g/mol 
MM of pAAV2/8 YF = 4523 g/mol 
 
The transfection mixture was vortexed while adding 15 ml 2x BBS dropwise. 2 ml of the solution 
were evenly distributed on each of the 15 culture dishes. Cells were incubated overnight at 37 
°C and 5 % CO2. On the next day, the medium was exchanged and cells were incubated 
overnight at 37 °C and 10 % CO2.  
The cells were harvested by scraping them from each dish and collecting them together with 
the medium in a 500 ml centrifuge tube. After centrifugation at 4000 rpm at 4 °C for 15 min 
(JA-10 rotor, J2-MC High speed centrifuge, Beckman Coulter), the medium was discarded and 
the pellet was resuspended in 7.5 ml lysis buffer. Cells were disrupted by three cycles of shock-
freezing in liquid nitrogen and thawing at 37 °C in a water bath. 
Lysis buffer 
NaCl 150 mM 
Tris-HCl pH 8.5 50 mM 
H2O add to 50 ml 
Filtrate sterilely  
 
3.7.2 Iodixanol gradient centrifugation 
Benzonase (VWR) was added to the virus-containing solution from step 3.7.1 to a final 
concentration of 50 U/ml and incubated for 30 minutes at 37 °C. After centrifugation at 4000 
rpm at 4 °C for 25 minutes, the pellet was discarded and the supernatant was transferred into 
a Quick-Seal Polypropylene Tube (39 ml, Beckman Coulter). Then, a gradient was prepared 
by underlayering the virus-containing supernatant with 7 ml of 15 %, 5 ml of 25 %, 5 ml of  
40 % and 6 ml of 60 % iodixanol using a long glass pipette and a Gilson MINIPULS3 pump. 
The tube was sealed with a Beckman Tube Topper and centrifuged at 70.000 rpm at 18 °C for 
105 minutes in an Optima L-80K ultracentrifuge using a 70 Ti rotor (Beckman Coulter). To 
collect the virus which migrated into the 40 % iodixanol layer, the tube top was perforated 
several times for pressure compensation. Afterwards, the tube was laterally punctured with a 
21-gauge needle directly above the 60 % layer. Then, the 40 % layer (approx. 5 ml) was 
extracted with a syringe.  
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15 % iodixanol  25 % iodixanol  
10x PBS 5 ml  10x PBS 5 ml 
1 M MgCl2  50 µl  1 M MgCl2  50 µl 
2.5 M KCl 50 µl  2.5 M KCl 50 µl 
5 M NaCl 10 ml  Optiprep 20.9 ml 
Optiprep (Progen) 12.5 ml  1 % phenol red 50 µl 
1 % phenol red 37.5 µl  H2O add to 50 ml 
H2O add to 50 ml    
 
40 % iodixanol  60 % iodixanol  
10x PBS 5 ml  1 M MgCl2  50 µl 
1 M MgCl2  50 µl  2.5 M KCl 50 µl 
2.5 M KCl 50 µl  Optiprep 50 ml 
5 M NaCl 10 ml  1 % phenol red 37.5 µl 
Optiprep 33.3 ml    
H2O add to 50 ml    
 
3.7.3 Anion exchange chromatography 
Anion exchange chromatography was applied to further purify the rAAVs using the ÄKTAprime 
plus system (GE Healthcare), the HiTrap Q FF sepharose column (GE Healthcare) and the 
PrimeView 5.31 software (GE Healthcare) according to the manufacturer’s instructions. Prior 
to use, the column was equilibrated with buffer A which was also used to dilute the virus 
suspension 1:1 before loading it onto the column via a loop injector (Superloop, 50 ml, GE 
Healthcare). Conductance and UV curves were recorded during the process providing 
information about the properties of the collected fractions. The bound molecules were eluted 
from the column with 2.5 M NaCl (buffer B, pH = 8.5). Desired virus-containing fractions, i.e. 
fractions within the plateau of the conductance curve, were combined for further processing. 
Buffer A 
Tris 20 mM 
NaCl 15 mM 
H2O add to 500 ml 
Adjust pH to 8.5  
 
3.7.4 Concentration of rAAVs  
To increase the concentration of rAAVs, combined fractions from step 3.7.3 were transferred 
into an Amicon Ultra-4 Centrifugal Filter Unit (100 kDa, Millipore) and centrifuged at 4000 rpm 
(JA-10 rotor, J2-MC High speed centrifuge, Beckman Coulter) at 20 °C for 20 minutes until the 
volume of the virus-containing solution was reduced to 500 µl. Then, the filter unit was washed 
with 1 ml 0.014 % Tween/PBS-MK and centrifugation was continued until 100 µl of 
concentrated virus suspension remained within the filter unit. 10 µl aliquots were prepared and 
stored at -80 °C until titer determination and subretinal injection. 
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Tween/PBS-MK 
10x PBS 50 ml 
1 M MgCl2 500 µl 
2.5 M KCl 500 µl 
Tween 20 0.014 % (v/v) 
H2O add to 500 ml 
 
3.7.5 rAAV titer determination 
Genomic rAAV titers were determined by qPCR using a standard curve generated by a serial 
dilution of the WPRE fragment which was amplified from the pAAV2.1 vector using the 
following primers: 
WPRE_F: AGTTCCGCCGTGGCAATAGG 
WPRE_R: CAAGGAGGAGAAAATGAAAGCC 
The WPRE element was purified (cf. chapter 3.3.3) and its concentration was measured via 
Nanodrop. The following equation (3) was used to calculate the concentration of the standard 
for 1010 copies of viral genome per 5 µl: 
c (pg/µl) = 1010 x 660 x 1012 pg/mol x WPRE fragment size / (6.022 x 1023/mol x 5 µl) (3) 
660 x 1012 pg/mol is the mean molar mass of one base pair and 6.022 x 1023/mol is the 
Avogadro constant. 
Based on this concentration, a 10-fold serial dilution was prepared with the first dilution 
comprising 1010 copies/5 µl and the last dilution containing 101 copies/5 µl. Subsequently, 
qPCR was run with triplicates of all ten dilutions and the standard curve was calculated by 
plotting the CT values against the logarithm of the dilution factors. The purified and 
concentrated rAAVs obtained in chapter 3.7.4 were diluted 1:500 in H2O and qPCR was 
performed. The genomic titers could be inferred from the resulting CT values and the 
corresponding values obtained in the standard curve. 
 
qPCR reaction mix 
SYBR Select Master Mix 10 µl 
WPRE_F (10 µM) 1 µl 
WPRE_R (10 µM) 1 µl 
Template 5 µl 
H2O add to 20 µl 
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3.8 Subretinal injection 
For subretinal injection of titer-matched rAAVs (109 particles/µl), 14-day-old wild type C57Bl/6J 
mice were weighted and anesthetized via an intraperitoneal injection of ketamine (40 mg/kg 
body weight) and xylazine (20 mg/kg body weight). The pupil was dilated by administering  
1 % atropine- and 0.5 % tropicamide-containing eye drops (Mydriaticum Stulln, Pharma Stulln 
GmbH). For injection, the eye fundus was focused using a surgical microscope (OPMI 1 FR 
pro, Zeiss). 1 µl of the virus solution was then applied subretinally using a NanoFil 10 µl syringe 
equipped with a 34-gauge beveled needle (World Precision Instruments). A correct subretinal 
application is indicated by the formation of a bleb, i.e. a temporal detachment of the retina at 
the injection site. Finally, the injected eye was treated with a gentamicin 5 mg/g and 
dexamethasone 0.3 mg/g containing eye salve (Dexamytrex, Dr. Gerhard Mann GmbH) and 
the mouse was kept in a cage heated to 37 °C until full anesthesia recovery.  
 
3.9 Immunohistochemistry 
Four weeks post injection, mice were euthanized and eyes were collected and transferred into 
0.1 M PB. Using a stereomicroscope (Stemi 2000, Zeiss) the eye was punctured at the ora 
serrata with a cannula (21G, Sterican, B. Braun) and fixed for 5 minutes in 4 % PFA. 
Afterwards, the cornea and lens were excised by cutting along the ora serrata with micro-
scissors (SuperFine Vannas, World Precision Instruments). Subsequently, the vitreous body 
was removed and the remaining retina-containing eyeball was fixed for 45 minutes in 4 % PFA. 
Hereafter, the eye was washed thrice for 5 minutes in 0.1 M PB. For cryoprotection, the eyeball 
was placed in 30 % sucrose and incubated overnight at 4 °C. After this, the eyeball was 
embedded in tissue freezing medium (Electron Microscopy Sciences) and frozen on dry ice. 
Then, 10 µm retinal cryosections were prepared using a cryostat (Leica CM3050 S, Leica), 
mounted on coated glass object slides (Superfrost Plus microscopic slides, Thermo Fisher 
Scientific) and stored at -20 °C prior to use.  
For immunohistochemistry, retinal cryosections were thawed at RT and rimmed by a 
hydrophobic barrier using a liquid blocker (Super PAP Pen Liquid Blocker, Science Services). 
Cryosections were rehydrated with 0.1 M PB for 5 minutes followed by a fixation step with 4 % 
PFA for 10 minutes. After washing thrice with 0.1 M PB for 5 minutes, the cryosections were 
incubated with the primary antibody diluted in 0.1 M PB containing 5 % ChemiBlocker 
(Millipore) and 0.3 % Triton X-100 overnight at 4 °C. On the next day, the cryosections were 
washed three times with 0.1 M PB for 5 minutes and incubated with the secondary antibody 
diluted in 0.1 M PB containing 2 % ChemiBlocker for 1.5 hours at RT. Then, cryosections were 
washed three times with 0.1 M PB for 5 minutes and the nuclei were stained with 5 µg/ml 
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Hoechst 33342 solution (Invitrogen) for 5 minutes. After a final washing step with 0.1 M PB for 
5 minutes, the sections were covered with Fluoromount-G Slide Mounting Medium (Thermo 
Fisher Scientific) and a cover slip. The cryosections were stored at 4 °C until analysis. All 
antibodies used are displayed in Table 3. 
 
0.1 M PB  4 % PFA  
Na2HPO4 x 2H2O 28.48 g  Paraformaldehyde 6 g 
NaHPO4 x H2O 5.52 g  0.1 M PB add to 150 ml 
H2O add to 2 l  Dissolve at 60 °C and filtrate sterilely  
Adjust pH to 7.4     
 
 
Table 3 Antibodies used for immunohistochemical stainings. 
Antibody Source Dilution 
rb anti-CNGB1a in-lab production 1:5000 
dk Cy-3 anti-rabbit IgG Jackson Laboratories 1:400 
rb anti-M-opsin  Millipore 1:300 
 
3.10 Confocal microscopy 
Images of immunolabeled retinal cryosections and isolated rod outer segments (cf. section 
3.12) were obtained by the TCS SP8 confocal laser scanning microscope (Leica) equipped 
with the following lasers: 552 nm, 514 nm, 488 nm, 405 nm. Images were acquired as confocal 
z-stacks using the LASX software (Leica) and processed with the ImageJ software (National 
Institutes of Health). 
 
3.11 Fluorescence-activated cell sorting (FACS) 
FACS was performed by Oliver Borsch and Tiago Santos-Ferreira in the group of Prof. Marius 
Ader at the TU Dresden. For FACS of rods and cones, the two different reporter mice neural 
retina leucine zipper- (Nrl-) EGFP [68] and cone-GFP [69] mice were used. In the Nrl-EGFP 
mice, reporter expression was driven by the rod-specific Nrl promoter. In the cone-GFP mice, 
GFP was driven by a 5’ regulatory sequence of the human red/green opsin gene. Two retinas 
per reporter mouse (6-8-week-old) were isolated and dissociated using the Papain 
Dissociation System (Worthington Biochemical Corporation) following the manufacturer’s 
instructions. Dissociated retinal cells were sorted with the BD FACSAria II SORP  
(BD Bioscience) device and collected according to their reporter fluorescence [70].  
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3.12 Isolation of photoreceptor outer segments 
Mice were sacrificed four weeks post injection for isolation of transduced photoreceptor outer 
segments. For this purpose, retinas were isolated and collected in a 1.5 ml reaction tube filled 
with 100 µl PBS. OSs were detached from the retina by vortexing 15-30 seconds and by 
centrifuging at 500 x g for 30 seconds. The OS-enriched supernatant was collected and used 
for subsequent FRET measurements. 
 
3.13 Förster resonance energy transfer (FRET) 
FRET is a commonly used method in optical microscopy to analyze protein-protein interactions 
and to determine atomic-scale distances (limited to approx. 10 nm) in living cells [71]. To 
perform FRET, each of the two putative interaction partners has to be tagged with a fluorescent 
molecule, one with the donor and the other one with the acceptor fluorophore. The excitation 
spectrum of the acceptor should overlap with the emission spectrum of the donor. One of the 
most popular fluorescent FRET pairs is cerulean (donor) and citrine (acceptor) [72, 73]. When 
both molecules are in close proximity, following photoexcitation the donor transfers parts of 
this excitation energy in a non-radiative fashion via long-range dipole-dipole interactions to the 
acceptor. This event results in a quenched donor and an augmented acceptor fluorescence. 
In this setting, fluorescent signals are measured via three different filter cubes (33- or three 
cube FRET). The fractional increase in the acceptor intensity also referred to as sensitized 
emission, can be utilized to calculate the FRET efficiencies (EA) [74-76]. The method enables 
a non-destructive qualitative and quantitative analysis of protein-protein interactions. 
In this study, FRET was used to quantify the effects of disease associated peripherin-2 point 
mutations on homomeric and heteromeric protein-protein interactions, i.e. oligomerization of 
peripherin-2 and its interaction with Rom-1, in HEK293T cells and in isolated rod outer 
segments. 
FRET measurements were conducted using a Leica DMI6000B inverted fluorescent 
microscope equipped with a R1527 photomultiplier detection system including a 
photomultiplier tube (Horiba). A xenon short arc lamp (UXL-75XE, Ushio Inc. Japan) combined 
with a DeltaRamX monochromator (Horiba) served as excitation source. Data were acquired 
with the FelixGX software (Horiba) and processed using MATLAB (MathWorks. Inc.) and Excel 
(Microsoft Corporation) [71]. Switching of filter cubes was done manually via a motorized filter 
wheel and with the following cubes being used: A donor cube containing a cerulean excitation 
filter (426-446 nm), a T455lp dichroic mirror and a cerulean emission filter (460-500 nm); an 
acceptor cube equipped with a citrine excitation filter (490-510 nm), a T515lp dichroic mirror 
and a citrine emission filter (510-550 nm); a FRET cube with a cerulean excitation filter  
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(426-446 nm), a T455lp dichroic mirror and a citrine emission filter (510-550 nm) (Chroma 
Technology). 
 
For FRET experiments, transfected HEK293T cells (cf. chapter 3.4.2) as well as isolated rod 
OSs (cf. section 3.12) were measured in a FRET imaging solution at RT. Fluorescence 
intensities were acquired from single cells co-expressing varying levels of donor- and acceptor-
tagged proteins with each filter cube. First, FRET ratios (FR) were calculated from the signal 
intensities according to the 33-FRET equation: 
 
FR = (SFRET – RD1 x Scer) / (RA1 x (Scitr – RD2 x Scer))      (4) 
 
RD1, RA1, and RD2 represent experimentally predetermined constants obtained from measured 
cells expressing only cerulean- or citrine-tagged molecules. These constants correct for bleed-
through of cerulean into the citrine channel (donor bleed-through, RD1), direct excitation of 
citrine by cerulean excitation (acceptor cross excitation, RA1), and the small proportion of 
cerulean excitation at the citrine excitation wave-length (donor cross talk, RD2) [76]. SFRET, Scer, 
and Scitr are the fluorescence signals measured from cells co-expressing cerulean- and citrine-
tagged molecules through the respective filter cube. 
 
FRET efficiencies (EA) at given cerulean/citrine molar ratios (MR) were derived from the 
following equation (5): 
 
EA = [FR – 1] x εcitrine (436) / εcerulean (436)       (5) 
 
The two factors εcitrine and εcerulean are the FRET setup-specific average molar extinction 
coefficients for citrine and cerulean. 
Binding curves were generated using equation (6): 
 
EA = EAmax x MR / [K + MR]         (6) 
 
EAmax represents the maximal FRET efficiency that can be calculated for saturated donor 
concentrations. K is an analog to the dissociation constant. 
 
FRET imaging solution 
NaCl 140 mM 
KCl 5 mM 
MgCl2 1 mM 
CaCl2 2 mM 
Glucose 10 mM 
HEPES sodium salt 10 mM 
H2O add to 50 ml 
Adjust pH to 7.4  
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3.14 Statistics 
For the comparison of two groups, the unpaired Student’s t-test was applied. For multiple 
comparisons, one-way ANOVA followed by Tukey’s or Dunett’s test were used. All values are 
given as mean ± SEM, and n is the number of independent measurements. Statistical 
significance is given as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001.
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4 Results 
4.1 rAAV PRPH2 minigenes confer efficient protein expression in rods
 and cones 
The entire human PRPH2 gene including the 5’ and 3’ untranslated region, the exons, and the 
introns comprises approx. 26 kb (Figure 6A, upper panel). Due to its large size and the limited 
genomic packaging capacity of rAAV vectors (4.7 kb), mRNA splicing cannot be analyzed on 
the native PRPH2 transcript. To overcome this issue, a peripherin-2 minigene (P-mg) was 
generated which contains the coding sequence of all three exons and shortened introns 
bearing the native splice sites (Figure 6A, lower panel). To enable monitoring of minigene-
derived protein expression, the P-mg was N-terminally fused to a citrine tag. The 
corresponding rAAV vector contained either a rod-specific human rhodopsin promoter (hRHO) 
or a cone-specific murine short wavelength opsin promoter (mSws) yielding the minigene 
vectors rP-mg and cP-mg, respectively (Figure 6B). The resulting rAAV particles were 
subretinally injected into two-week-old (P14) wild type (WT) mice. Correct splicing of rP-mg 
and cP-mg results in a peripherin-2 protein with a molecular weight of approx. 66.5 kDa (Figure 
6C). The expression was analyzed three weeks post injection by monitoring the citrine 
fluorescence on retinal slices from injected animals. As expected, in transduced rods and 
cones, citrine signal was exclusively found in the outer segments (Figure 6D and E). 
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Figure 6 Design and expression of the PRPH2 minigene in rod and cone photoreceptors. (A) Exon-intron 
structure of native human PRPH2 (upper panel) and the derived P-mg (lower panel). Intron 1 and 2 were largely 
deleted except for the sequences (181-200 bp) flanking exons 1-3 as indicated. (B) Minigenes used for  
rAAV-mediated expression of peripherin-2 in rods (rP-mg) and cones (cP-mg) by means of specific promoters. 
hRHO, human rhodopsin promoter; mSws, murine short wavelength opsin promoter. Citrine was fused to exon 1 
allowing antibody-free visualization of minigene-derived peripherin-2. (C) Topology of correctly spliced  
citrine-tagged peripherin-2. (D and E) Immunohistology of transduced murine retinas performed three weeks after 
the injection of WT mice (P14) with rP-mg (D) and cP-mg (E). A CNGB1a (B1a) antibody served as rod OS marker. 
A M-opsin (M-ops) antibody was used as cone OS marker. Scale bar represents 20 µm. 
 
4.2 In silico mRNA splice analysis of exon 2-specific peripherin-2 point 
 mutations 
Most disease-causing mutations in PRPH2 are found within exon 2 encoding for the distal part 
of the D2 loop and the proximal half of transmembrane domain 4. For this reason, an initial in 
silico analysis was performed to predict the potential effects of 30 exon 2-specific peripherin-2 
point mutations on mRNA splicing using the ASSEDA and NNSplice splice prediction software. 
For the majority of the mutants, various effects on splicing were predicted such as the 
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generation of novel donor or acceptor splice sites and the abolition or generation of binding 
sites for exonic splice enhancers (ESEs) or exonic splice silencers (ESSs) (cf. Supplementary 
Table 1). Among the mutations with predicted splice defects, 11 were randomly chosen for 
further experimental analysis. Six of these mutants are associated with rod-dominant adRP, 
whereas the remaining five are found in patients suffering from different types of cone diseases 
(Table 4). Some of these mutations have been functionally characterized on protein level in 
previous studies (e.g. C214S) [77, 78], however, none of these studies addressed the potential 
impacts of the single mutants on mRNA splicing.  
 
Table 4 Exon 2-specific peripherin-2 point mutations analyzed in this study [43, 79-88]. 
Mutation  Disease References 
c.584G>T; p.R195L cone and cone-rod dystrophy  Yanagihashi et al. 2003  
c.594C>G; p.S198R adRP Sullivan et al. 2006  
c.625G>A; p.V209I adult foveomacular vitelliform dystrophy Coco et al. 2010  
c.629C>T; p.P210L adRP Budu et al. 2001  
c.635G>C; p.S212T adult foveomacular vitelliform dystrophy Felbor et al. 1997 
c.641G>C; p.C214S adRP Saga et al. 1993  
c.658C>T; p.R220W pattern dystrophy Payne et al. 1998  
c.659G>A; p.R220Q pattern dystrophy Jacobson et al. 1996  
c.676C>G; p.Q226E adRP Rodriguez et al. 1994  
c.736T>C; p.W246R adRP Kohl et al. 1997  
c.745G>A; p.G249S adRP Renner et al. 2009  
 
4.3 Comparative splice analysis of WT and mutant peripherin-2 minigenes
 in rods and cones 
Viral particles containing the different mutant minigenes were subretinally injected into WT 
mice on P14. To analyze mRNA splicing of WT (perWT) and mutant peripherin-2 (perMT) 
transgenes, RNA was isolated and pooled from four retinas of four injected animals three 
weeks after injection. RT-PCR (Figure 7A) was performed with minigene-specific primers, 
indicated as arrows in Figure 7B. Three different splice isoforms were detected for perWT and 
perMT minigenes in rods and cones: 1) the unspliced variant containing both introns  
(1699 bp), 2) the variant with retained intron 1 (1319 bp), and 3) the correctly spliced transcript 
(919 bp) (Figure 7A, B). One mutation, perG249S, associated with adRP gave rise to a fourth 
splice product containing an in-frame deletion of 90 bp at the 3’ end of exon 2 due to the use 
of a novel donor splice site (DS) (Figure 7A, B). 
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Figure 7 Splice analysis of perWT and perMT minigenes in rods and cones. (A) Representative RT-PCR from 
cDNA generated from total RNA isolated from transduced retinas of WT mice three weeks after injection with WT 
and mutant rP-mg (left) or cP-mg (right) on P14. Ctrl, control containing cDNA from non-transduced retina. The 
individual bands of the relevant splice products are numbered (1-4) and marked by arrowheads. (B) Schematic 
representation and sequence analyses of the single minigene-derived splice variants detected in (A). For RT-PCR, 
primers were used binding to the 3’ end of citrine and 5’ end of exon 3 of peripherin-2 as indicated by the arrows.  
1 and 2, Unspliced (1) and intron 1 retention (2) transcripts lead to a frameshift resulting in a premature stop codon 
immediately after exon 1. The corresponding protein lacks the distal half of the D2 loop, T4, and the C-terminus. N, 
N-terminus; C, C-terminus. 3, Sequence results displaying the exon boundaries of the correctly spliced transcript. 
Left, topology of correctly spliced peripherin-2. 4, Sequencing results obtained for perG249S. Upper panel, scheme 
showing perG249S before (top) and after splicing (bottom). Lower panel, left, predicted impact of perG249S on protein 
level. The generation of a novel donor splice site (DS) results in an in-frame deletion of 30 amino acids (aa) 
comprising the part of peripherin-2 covered by the brown transparent rectangle. Middle and right, 
Electropherograms showing the impact of perG249S before and after splicing. Right, the position of the novel DS is 
indicated by an arrow and the position of the mutation is highlighted by an arrowhead. All sequencing reactions 
were performed on bands isolated from (A). (C-E) Semi-quantitative analysis of the relative intensities obtained for 
the unspliced (C), intron 1 retention (D), and correctly spliced (E) peripherin-2 transcripts. For each perWT and perMT 
minigene, the mean percentage of the band intensities of these three variants relative to the total band intensity 
(given as sum of the single band intensities) was calculated from five RT-PCR analyses performed with a variable 
number of cycles (20-28 for rods and 26-33 for cones, cf. Figure 8). Differences in intensities between the rod and 
cone perMT to the corresponding perWT minigene were analyzed for significance using one-way ANOVA followed by 
Dunett’s test. All data were shown as mean values and error bars represent the standard of the mean (SEM).  
*, p < 0.05; **, p < 0.01; ***, p < 0.001. 
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To allow for more precise statements concerning the relative amounts of the three different 
splice isoforms (unspliced, intron 1 retention, and correctly spliced) in rods and cones, 
quantitative real-time PCR (qPCR) was used. qPCR was performed with the pooled RNA 
isolated from retinas transduced with WT rP-mg and cP-mg utilizing the minigene-specific 
primers. The linear range of amplification was detected between 20-28 cycles for WT rP-mg in 
rods and between 26-33 cycles for WT cP-mg in cones (Figure 8).  
 
 
Figure 8 Determination of the linear amplification range of RT-PCR for peripherin-2 minigenes using qPCR. 
Representative qPCR from retinas injected with perWT minigenes harboring a rod- (hRHO, rP-mg) or a cone- (mSws, 
cP-mg) promoter. For qPCR, the same pooled retina samples and the same primers were used as described in 
Figure 7B. The dashed lines represent the window of cycles falling within the linear amplification range for rP-mg 
(cycles 20-28, magenta) and cP-mg (cycles 26-33, green). ΔRn (delta Rn), the magnitude of the signal generated 
by the given set of PCR conditions. 
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Based on these findings, five technical RT-PCR replicates were performed for each peripherin-
2 construct with cycle numbers lying within the respective range of linear amplification in rods 
and cones. The mean percentage of unspliced, intron 1 retention, and correctly spliced 
transcripts relative to the sum of band intensities was calculated for all peripherin-2 minigenes 
(cf. Supplementary Table 2). This analysis revealed profound differences in the relative 
percentage of the different splice isoforms in rods and cones. These differences were not only 
observed when comparing the splicing of perWT minigenes in rods and cones, but also when 
relating the effect of each perMT to the corresponding perWT in the given cell type. Regarding 
perWT in rods, the major splice isoform was the correctly spliced transcript with 70.1 %, whereas 
splicing of perWT in cones yielded only very low amounts of this variant (1.64 %, Figure 7E). In 
contrast to rods, splicing of perWT in cones predominantly resulted in the unspliced isoform with 
87.1 % (Figure 7C). For the intron 1 retention variant, a moderate, but not significant difference 
was found in rods and cones (Figure 7D). For the perG249S mutant, the correctly spliced isoform 
was reduced to 56.2 % in rods (Figure 7E). This reduction most likely results from the 
generation of the novel donor splice site observed for this mutation (Figure 7B). In cones, the 
three mutants perV209I, perR195L, and perR220Q resulted in a strong increase in the correctly 
spliced isoform accompanied by a simultaneous decrease in the unspliced transcript (Figure 
7C, E). Taken together, these results indicate cell type- and mutation-specific effects on mRNA 
splicing of peripherin-2 in rod and cone photoreceptors.  
 
4.4 Quantitative analysis of native peripherin-2 splice isoforms 
The splicing analysis shown in Figure 7A was performed with human peripherin-2 minigenes 
expressed in murine photoreceptors. However, it is conceivable that the endogenous ratios of 
the single peripherin-2 splice isoforms might differ in human and in mouse photoreceptors, 
which in turn would impede the interpretation of this minigene-based assay. To investigate 
whether mRNA splicing of peripherin-2 in mouse photoreceptors is similar to that of human 
peripherin-2, endogenous levels of peripherin-2 splice isoforms in human and murine retina 
were assessed via qPCR using human or mouse retinal WT cDNA. For this purpose, two 
primer sets were utilized specific for the two human (hPRPH2) or murine (mPrph2) peripherin-
2 transcripts mirroring the splice isoforms detected in the minigene-based splicing assay 
(Figure 9A). For the detection of the correctly spliced transcript, primers binding to exon 1 and 
exon 3 (P-cs_F and P-cs_R) were used. Due to the large size of the interjacent native introns 
(23 kb for human and 12 kb for murine intron 1 and intron 2, cf. Figure 6A and Figure 9A), 
peripherin-2 isoforms containing the introns are most likely not amplified under the qPCR 
conditions. To specifically amplify the unspliced peripherin-2 isoform, primers binding to the 
intronic regions flanking exon 2 were selected (P-us_F and P-us_R). Both primer sets led to 
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detectable qPCR products in human and mouse retina with the relative expression being 
slightly higher for each of the two peripherin-2 transcripts in the human retina (Figure 9B). As 
rods account for ≥ 95 % of the photoreceptor population in both, the human and mouse retina, 
these results most likely reflect the splicing of peripherin-2 minigenes in rods. Accordingly, the 
correctly spliced peripherin-2 transcript was much higher expressed compared to the unspliced 
variant (10.6 ± 0.68 vs 0.21 ± 0.03 in the human retina, and 5.60 ± 0.29 vs 0.14 ± 0.03 in the 
murine retina). No differences between the human and mouse peripherin-2 expression were 
identified when plotting the ratio of the unspliced to the correctly spliced isoforms (0.10 ± 0.01 
for human retina vs 0.13 ± 0.02 for murine retina, Figure 9C). These results strongly indicate 
that in both qualitative and quantitative terms, splicing of peripherin-2 is very similar in the 
human and mouse retina. 
The minigene-based splicing analysis revealed that cones significantly differ from rods in the 
relative abundance of the correctly spliced and the unspliced peripherin-2 isoforms  
(Figure 7). To investigate whether this is also the case in a more native setting, fluorescence-
activated cell sorting (FACS) was used to purify rods and cones from 6-8-week-old reporter 
mice. The purity of sorted rods and cones was assessed by comparing the transcript levels of 
cell type-specific genes, i.e. rhodopsin (Rho) as marker for rods and M-opsin (Opn1mw) as 
marker for cones. Sorted cones were only slightly contaminated with rods (about 3.6 %, Figure 
9D). This minor contamination is not expected to have noticeable impacts on the interpretation 
of the results. In accordance with the qPCR results obtained for the native retina shown in 
Figure 9B, the correctly spliced peripherin-2 transcript in sorted rods was much higher 
expressed compared to the unspliced variant (16.7 ± 20.71 vs 0.95 ± 0.07). Unlike rods, in 
sorted cones the correctly spliced peripherin-2 isoform was only moderately increased 
compared to the unspliced transcript (5.45 ± 0.44 vs 2.71 ± 0.19). Additionally, the data reveals 
that the expression level of correctly spliced peripherin-2 is markedly decreased in cones which 
was accompanied by an increase in the expression of the unspliced transcript. The differential 
expression of the single peripherin-2 isoforms in the two cell types was further emphasized by 
comparing the ratios of the unspliced to the correctly spliced variants (0.06 ± 0.004 in rods vs 
0.49 ± 0.04 in cones, Figure 9E). These results are largely compatible with the data acquired 
from the minigene-based splicing analysis demonstrating that the relative endogenous levels 
of the correctly spliced and unspliced peripherin-2 isoforms differ significantly between rods 
and cones.  
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Figure 9 Quantification of peripherin-2 splice isoforms in native human and murine retinas. (A) Exon-intron 
structure of human PRPH2 (hPRPH2, upper panel) and mouse Prph2 (mPrph2, lower panel). Binding positions of 
primers used for qPCR are indicated by arrows. To detect correctly spliced human (hP-cs) or murine peripherin-2 
(mP-cs), the P-cs_F and P-cs_R primer combination was used. For the detection of unspliced human (hP-us) or 
murine peripherin-2 (mP-us), the P-us_F and P-us_R primer set was applied (cf. Supplementary Table 8).  
(B) qPCR from pooled human (gray boxes) or murine (black boxes) total retinal RNA, isolated from two (human) or 
four (mouse) biological samples. The single values are as follows: hP-cs, 10.6 ± 0.67; hP-us, 0.21 ± 0.03;  
mP-cs, 5.60 ± 0.29; mP-us, 0.13 ± 0.03. All data are given as mean values and error bars represent the SEM. Three 
technial replicates were performed for each primer set. (C) Relative ratios given as mean values ± SEM of the single 
unspliced transcripts to the corresponding correctly spliced isoform from human (0.10 ± 0.01) or murine (0.13 ± 
0.02) retina. A significance test was conducted using the two-tailed t-test (p = 0.26). n.s., not significant. (D) qPCR 
form sorted murine rods (red boxes) and cones (black boxes). It was performed with cDNA obtained from pooled 
rods sorted from six animals (yielding 100.000 cells) and pooled cones sorted from four animals (yielding 27.000 
cells). For cDNA synthesis, identical total RNA concentrations of isolated rods and cones (50 ng each) were used. 
Three technical replicates were conducted for each primer combination. All data are given as mean values and 
error bars represent the SEM. The single values for sorted rods are as follows: Rho, 146.9 ± 10.2; Opn1mw, 1.25 
± 0.16; P-cs, 16.7 ± 0.71; P-us, 0.95 ± 0.07. Expression in sorted cones yielded following values: Rho, 5.27 ± 0.14; 
Opn1mw, 6.38 ± 0.13, P-cs, 5.45 ± 0.44; P-us, 2.71 ± 0.19. P-cs rods vs cones: p = 0.0002; P-us rods vs cones: p 
= 0.001. (E) Relative ratios of the unspliced transcripts to the corresponding correctly spliced isoform from sorted 
rods and cones. Significance analysis was conducted with the two-tailed t-test (p = 0.0003). 
 
4.5 Peripherin-2 isoform encoded by exon 1 is mislocalized in 
 photoreceptors 
Expression of PRPH2 minigenes shown in Figure 6D and E indicates that the citrine-tagged 
peripherin-2 protein is properly expressed and localized in the OSs of murine rods and cones. 
However, considering that all three minigene-derived splice isoforms harbor the fluorophore, 
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the detection of citrine fluorescence does not allow discriminating which of the isoforms and to 
which extent they are expressed on protein level. Correctly spliced, fluorophore-tagged full-
length peripherin-2 is known to be properly localized in OSs [89]. However, unspliced 
peripherin-2 and the intron 1 retention isoform contain a premature stop codon directly after 
exon 1 (cf. Figure 7B) and their OS localization has not been analyzed in previous studies. The 
translation of these two transcripts would yield a truncated protein lacking the distal part of the 
D2 loop, transmembrane domain 4, and subsequent downstream sequence (Figure 10A). 
Translation and protein expression of these peripherin-2 isoforms could lead to one of the four 
following scenarios: i) The two splice variants are translated into protein, which is stably 
expressed, but mislocalized to the inner segments. ii) Both isoforms are translated into protein 
showing correct localization. iii) The two variants are translated into protein, but the protein is 
degraded. iv) The isoforms are degraded on mRNA level via the nonsense-mediated mRNA 
decay (NMD) mechanism due to the presence of a premature stop codon. The first option can 
be excluded as no mislocalized protein was detected in transduced photoreceptors expressing 
the perWT minigene. To differentiate between the remaining three alternatives, the peripherin-
2 variant harboring a stop codon directly after exon 1 (Figure 10A) was expressed in rods and 
cones. This truncated peripherin-2 mirrors the protein translated from the unspliced or intron 1 
retention isoforms. However, unlike the two minigene-born transcripts, this variant does not 
contain a premature stop codon and the mRNA can thus not be degraded by the NMD 
mechanism. This truncated peripherin-2 was completely mislocalized in the inner segments of 
rods (rP-trunc) and cones (cP-trunc) (Figure 10B and C). Hence, scenarios ii) and iii) proposing 
correct localization or protein degradation of the two isoforms can be excluded. Consequently, 
the most likely scenario is that the two splice isoforms bearing the premature stop codon are 
not translated into protein, presumably as a result of mRNA degradation due to NMD. 
 
 
Figure 10 Impaired OS targeting of truncated peripherin-2. (A) The truncated peripherin-2 construct contains 
only exon 1 followed by a downstream stop codon (indicated by “X”) mimicking translation from the intron 1 retention 
and unspliced isoforms (upper panel). Lower panel, Topology of the truncated peripherin-2 protein.  
(B and C) Immunohistology of transduced murine retinas showing rod- (B) and cone-specific (C) expression of the 
truncated peripherin-2. In both, rods and cones, truncated peripherin-2 is not transported to the OSs and is almost 
exclusively present in the ISs and somas of the photoreceptors. B1a and M-ops (red) served as rod and cone OS 
markers, respectively. Scale bar represents 20 µm. 
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4.6 Protein expression and localization of perMT in rods and cones 
Next, protein expression and localization of the disease-associated peripherin-2 mutations 
were addressed in transduced rods and cones (Figure 12 and 11). The mutant expression was 
assessed on retinal sections three weeks after the subretinal delivery of rAAVs to P14 WT 
mice. Cone dominant mutations were correctly localized to the cone OSs (Figure 11A-E). In 
the western blot analysis, all mutant proteins migrated at the same size as perWT (approx. 66.5 
kDa), however, their expression levels differed among each other (Figure 11F). Particularly, 
the three mutants perV209I, perR195L, and perR220Q displayed a strongly increased protein 
expression compared to perWT (Figure 11F and G). These findings are consistent with the 
strongly increased splicing efficiency of the correctly spliced PRPH2 isoform that was observed 
for these mutants in cones (cf. Figure 7E).  
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Figure 11 In vivo expression of cone-dominat perMT. (A-E) Immunohistology of transduced retinas expressing 
the single cone-disease associated peripherin-2 constructs under the control of the mSws promoter as indicated. A 
M-opsin antibody (M-ops, red) served as cone OS marker. Scale bar represents 20 µm. (F) Western blot analysis 
from membrane preparations of four murine retinas transduced with the minigenes shown in A-E. All retinas were 
dissected three weeks post injection. Ctrl, Membrane preparation from non-injected control retinas. Peripherin-2 
was detected via an anti-GFP antibody recognizing the citrine tag. An antibody detecting the murine alpha subunit 
of ATPase (anti-ATPase) served as loading control. (G) Semi-quantitative analysis of the results shown in (F). For 
determining the relative band intensities, three technical replicates were performed and peripherin-2 expression 
was normalized to the expression of ATPase. All data are given as mean values ± SEM. Statistical analysis was 
done with one-way ANOVA followed by the Dunett’s test. *, p < 0.05; **, p < 0.01; ***, p < 0.001. n.s., not significant. 
 
Results 47 
When compared to the cone-dominant perMT, rod-dominant perMT revealed more diverse 
effects. Two out of the six mutants, perC214S and perP210L, were completely mislocalized to the 
rod inner segments (Figure 12A and B). In contrast to perC214S showing an evenly distributed 
cytosolic expression, perP210L was found in large vesicular-like structures.  
Additionally, in the western blot analysis and in retinal cryosections, perC214S and perP210L 
together with two further mutants, perS198R and perG249S, showed lower expression compared 
to perWT (Figure 12G, H). The strongest reduction was observed for perC214S and perS198R, 
followed by the perP210L and the perG249S mutant. The remaining two mutants, perQ226E and 
perW246R, displayed perWT-like protein levels (Figure 12G, H).  
Furthermore, the strong reduction of the 66.5 kDa band for the perS198R and perP210L mutants 
was accompanied by an increased expression of an additional band at approx. 42 kDa. This 
band was only weakly detectable for perWT and most likely results from protein degradation. 
 The moderate decrease in protein expression observed for the perG249S mutation is 
presumably due to the generation of a novel donor splice site (cf. Figure 7B, E) as this reduces 
the relative amount of the correctly spliced peripherin-2 transcript for this mutant. This novel 
donor splice site leads to a deletion of 30 amino acids comprising the most distal part of the 
D2 loop domain and the proximal half of the transmembrane domain 4 (Figure 7B). This 
deletion reduces the molecular size of the protein by approx. 3.5 kDa, yielding a molecular 
mass of 63 kDa. However, as no band was detected for perG249S at this size in the western blot, 
the aberrantly spliced isoform is most likely either degraded on the mRNA or protein level. 
Taken together, diverse disease mechanisms were observed for four out of the six adRP-linked 
perMT including aberrant mRNA splicing, protein degradation, and protein mislocalization. 
However, all of these mechanisms lead to a decreased protein expression for these mutants 
in rods. In contrast, three out of the five perMT associated with cone diseases result in increased 
protein expression in this photoreceptor type.  
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Figure 12 In vivo expression of rod-dominat perMT. (A-F) Immunohistology of transduced retinas expressing the 
single adRP-linked peripherin-2 constructs under the control of the hRHO promoter as indicated. A CNGB1a 
antibody (B1a, red) served as rod OS marker. Scale bar represents 20 µm. (G) Western blot analysis from 
membrane preparations of four murine retinas transduced with the minigenes shown in (A-F). All retinas were 
dissected three weeks post injection. Ctrl, Membrane preparation from non-injected control retinas. The arrow 
indicates a degradation band detected at 42 kDa. Peripherin-2 was detected via an anti-GFP antibody recognizing 
the citrine tag. An antibody detecting the murine alpha subunit of ATPase (anti-ATPase) served as loading control. 
(H) Semi-quantitative analysis of the results shown in (G). For determining the relative band intensities, three 
technical replicates were performed and peripherin-2 expression was normalized to the expression of ATPase. All 
data are given as mean values ± SEM. Statistical analysis was assessed using one-way ANOVA followed by the 
Dunett’s test. *, p < 0.05; **, p < 0.01; ***, p < 0.001. n.s., not significant. 
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4.7 Splicing and protein expression of a rod-dominant perMT in cones and a 
 cone-dominant perMT in rods 
So far, mRNA splicing and protein expression of the rod- and cone-specific perMT were 
exclusively analyzed in the photoreceptor type reported to be affected by the given mutation. 
In order to exclude the possibility that mutations also impact on these processes in the 
photoreceptor type that is not primarily affected by the mutation, the rod-dominant perW246R 
mutant was expressed in cones while the cone-dominant perR220W mutant was expressed in 
rods (Figure 13). However, for both mutants, protein localization (Figure 13A, F), mRNA 
splicing (Figure 13B, C, G, H), and protein expression levels (Figure 13D, E, I, J) remained 
unaffected and were indistinguishable from the corresponding perWT. 
 
 
Figure 13 Cross-expression of a rod-dominant perMT in cones and a cone-dominant perMT in rods. Protein 
localization (A, F), mRNA splicing (B, C, G, H), and protein expression (D, E, I, J) of the cone-specific perR220W 
mutant in rods (A-E) and the rod-specific perW246R mutant in cones (F-J). All experimental conditions (age and 
number of injected mice, immunolabeling of retinal slices, time points of RNA and protein isolation, number of cycles 
used for RT-PCR, and type of data presentation) were identical to those described in Figure 6, 7, 11 and 12. For 
the semi-quantitative analysis of mRNA splicing (C, H) and protein expression (E, J) in rods and cones, three 
technical replicates were performed. Significance test was conducted using the two-tailed t-test. p-values are as 
follows: C, punspliced = 0.91; C, pcorrectly spliced = 0.76; H, punspliced = 0.74; H, pcorrectly spliced = 0.87; E, p = 0.87; J,  
p = 0.25. Scale bars in A and F represent 20 µm. 
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4.8 Impact of the disease-linked perMT on homo- and heteromeric protein-
 protein interactions 
As demonstrated in Figure 11 and Figure 12 in chapter 4.6, in contrast to perC214S and perP210L, 
none of the other nine mutants affected rod OS targeting. One possible mechanism explaining 
the mislocalization of perC214S and perP210L in rod photoreceptors could be that these mutations 
impact on the binding of the mutant protein to perWT and/or to Rom-1. As mentioned in the 
introduction, peripherin-2 can form homomeric peripherin-2/peripherin-2 and heteromeric 
peripherin-2/Rom-1 complexes. To investigate whether the disease-linked peripherin-2 
mutations affect these complexes, co-immunoprecipitation experiments from HEK293T cells 
co-transfected with the single mutants and perWT or Rom-1 were performed. As the two 
mutations perR220Q and perR220W affect the same arginine residue at position 220, only one of 
these mutants (perR220Q) was analyzed in this experiment. 
As is evident from Figure 14, only the two rod-dominant mutations perC214S and perP210L showed 
a markedly reduced binding to both perWT and Rom-1 (Figure 14B, C). In accordance with 
previous studies [28, 77], this suggests that peripherin-2 mislocalization might correlate with 
impaired protein complex formation.  
 
4.9 P210 and C214 are crucial for the proper folding of the distal D2 loop 
The proline at position 210 (P210) and the cysteine at position 214 (C214) are located within 
a highly conserved motif among tetraspanins, the PxxCC motif whose function has not been 
fully clarified yet [90]. The reduced binding of perC214S and perP210L to perWT suggests that these 
residues might either be crucial for proper folding of peripherin-2 or could represent the protein-
protein interaction interface. A recent study utilizing CD spectroscopy indicated that perC214S 
impairs protein folding by increasing the percentage of β-sheets accompanied by a decrease 
in helices in the D2 loop [91]. However, it was not fully clarified which part(s) of the D2 loop is 
(are) affected by this mutation. In order to address this issue more directly, a protease cleavage 
assay was designed and performed on membrane preparations from HEK293T cells 
expressing the citrine-tagged perWT and perMT transgenes (Figure 14D). Membrane 
preparations are expected to preserve the native protein structure as they are performed 
without any detergents or reducing agents [92]. Improper folding can lead to the masking of 
existing or to an exposure of hidden protease cleavage sites and therefore alter the number of 
cleavage sites accessible for the endogenously expressed proteases present in the membrane 
preparations.  
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Figure 14 Effects of peripherin-2 mutants on protein-protein interactions and D2 loop folding. (A) The dashed 
rectangle marks the distal part of the D2 loop which is schematically enlarged below. The hitherto identified disease-
associated perpiherin-2 mutations in this region are highlighted in green. The positions of the mutants analyzed in 
(B-D) are indicated by red arrows (for perP210L and perC214S) or by black arrowheads in case of the remaining 
mutants. The calculated protease cleavage sites from (D) are marked by a white (corresponding to the 42.5 kDa 
band) or black (corresponding to the 52.4 kDa band) pacman. The position of the peptide (amino acids 201-220) 
used in the competition assay shown in (E) (pept201-220) is highlighted by the gray line. (B-C) Co-IPs from membrane 
preparations of HEK293T cells transiently transfected with the respective N-terminally citrine-tagged mutants and 
C-terminally myc-tagged perWT (perWT-myc, B) or Rom-1 (Rom-1-myc, C). The mutants were detected using a GFP 
antibody (anti-GFP) recognizing the citrine-tag whereas perWT-myc and Rom-1-myc were detected via a myc-
specific antibody (anti-myc). IB, Immunoblotting. (D) Protease cleavage assay performed with membrane 
preparations from HEK293T cells transiently transfected with the citrine-tagged perMT and perWT as indicated. The 
molecular weight of the single bands (marked by arrows) was calculated from five independent western blot 
experiments. (E) Co-IPs from membrane preparations of HEK293T cells co-transfected with citrine- and myc-tagged 
perWT in presence (left lane, 10mM) or absence of the peptide. 
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Using the same GFP antibody recognizing the N-terminally citrine-tagged peripherin-2 
constructs (cf. chapter 4.8), three bands at 61.5 kDa, 52.4 kDa and 42.5 kDa could be detected. 
The 61.5 kDa band represents the full-length citrine-tagged peripherin-2. Its calculated size is 
66.5 kDa; however, in the presence of protease inhibitors, full-length perWT always migrated 
as a 61.5 kDa band. The 52.4 kDa and 42.5 kDa bands could only be detected in the absence 
of protease inhibitors and upon incubation of the samples at 37 °C. Using the 61.5 kDa perWT 
band as reference, the putative cleavage sites for the 52.4 kDa and 42.5 kDa bands were 
calculated. The 42.5 kDa band indicates protein cleavage around the highly conserved 
tetraspanin CCG motif (Figure 14A) [90]. This band could be observed for all peripherin-2 
constructs suggesting proper folding in this part of the protein. In contrast, the 52.4 kDa band 
was completely absent for perC214S and perP210L. The putative protease cleavage site for the 
52.4 kDa band is calculated to be located within the distal part of the D2 loop next to the 
transmembrane domain 4 (Figure 14A). Collectively, these findings indicate that perC214S and 
perP210L lead to a structural rearrangement of the distal part of the D2 loop.  
A recent study postulated that peripherin-2 residues 165-182 are crucial for homomeric 
protein-protein interactions [93]. However, it has not been clarified whether flanking regions 
involving the perC214S and perP210L residues could also have an impact on this type of 
interaction. To investigate this possibility, a peptide competition assay was performed using a 
peptide corresponding to the residues 201-220 of native human peripherin-2 (Figure 14A and 
E). In case the positions P210 and C214 are involved in peripherin-2 homomerization, the 
peptide should compete with this binding and, thus, lead to a reduction of homomeric protein-
protein interactions. In subsequent co-IP experiments, however, even in the presence of a very 
high peptide concentration (10 mM), no changes in the perWT-perWT interaction compared to 
the peptide-free approach were detectable (Figure 14E). These results indicate that the region 
comprising the residues 201-220 is most likely not directly involved in homomerization of 
peripherin-2. 
 
4.10 Quantification of perWT, perMT, and Rom-1 protein-protein interactions
 in HEK293T cells using FRET 
33-FRET can be used to quantify homo- and heteromeric interactions of photoreceptor-specific 
proteins such as peripherin-2 [89, 94]. In particular, this method can be applied to determine 
the relative binding affinities of these proteins in HEK293T cells [89]. Thus, FRET was used in 
this study to examine the specific binding characteristics of the different homo- and heteromeric 
perWT, perMT, and Rom-1 protein complexes (Figure 15). To calculate the binding curves, the 
relative expression of cerulean and citrine (given as molar ratio, cer/citr MR) needs to vary 
between the single cells co-expressing these FRET fluorophores. When plotting the FRET 
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efficiency (EA) values against the corresponding cer/citr MR, sufficient variabilities in the 
expression of both fluorophores for each FRET combination were obtained. EAmax, representing 
the maximal FRET efficiency, was calculated according to equation (6) in chapter 3.13 and is 
proportional to the binding strength of the respective protein complex in the equilibrium. 
Analysis of EAmax for the different perWT and perMT combinations provided several important 
conclusions:  
i) Robust and unusually high EAmax values for the perWT only FRET pair were obtained  
(34.2 %, Figure 15A and Supplementary Table 3). These EAmax values almost reach the highest 
theoretically possible FRET efficiency of 40 % for proteins fused to bulky fluorophores like 
cerulean or citrine emphasizing the strength of homomeric peripherin-2 protein-protein 
interactions [95].  
ii) In comparison to perWT, the perP210L only (30.7 %, Figure 15B and Supplementary Table 3) 
and perC214S only (26.5 %, Figure 15C and Supplementary Table 3) FRET pairs displayed just 
a slight decrease in EAmax, indicating that both mutants are still largely able to self-interact.  
iii) In line with the findings obtained from the co-IP experiments shown in Figure 14B,  
perWT-perP210L (9.44 %) as well as perWT-perC214S (8.58 %) complexes resulted in a robust 
decrease in EAmax (Figure 15D, E and Supplementary Table 3). This indicates that the protein 
complex formation is strongly impaired but not completely abolished for the perWT-perP210L and 
perWT-perC214S combinations. 
Next, the EAmax values of peripherin-2-Rom-1 combinations were analyzed. EAmax of the  
perWT-Rom-1 interaction was considerably decreased (15.6 %) compared to the perWT only 
(34.2 %) interaction suggesting that heteromeric perWT-Rom-1 complexes bind less tight than 
their homomeric perWT only counterparts (Figure 15F and Supplementary Table 3). 
Furthermore, both combinations, perP210L-Rom-1 and perC14S-Rom-1, exhibited a reduction in 
their EAmax values compared to the perWT-Rom-1 interaction (6.58 % and 6.32 %, respectively, 
Figure 15G, H and Supplementary Table 3).  
Finally, also the percentage of EAmax reduction for both mutants relative to the perWT only and 
the perWT-Rom-1 FRET pairs were calculated. The EAmax values were reduced to 28 % of the 
perWT only value for the perWT-perP210L and to 25 % for the perWT-perC214S complexes. In 
contrast, EAmax values were only reduced to 42 % of the perWT-Rom-1 FRET pair value in the 
case of the perP210L-Rom-1 and to 40 % for the perC14S-Rom-1 combinations (Supplementary 
Table 3). These results indicate that the binding of both peripherin-2 mutants to Rom-1 is less 
severely affected than their binding to perWT. However, despite more or less strongly reduced 
efficiencies, perP210L and perC14S in principal retain their ability to self-interact and to form 
complexes with both, perWT and Rom-1. 
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Figure 15 Quantification of perWT, perMT, and Rom-1 protein-protein interactions in HEK293T cells using 
FRET. (A-H) FRET experiments performed in living HEK293T cells transiently transfected with the respective 
cerulean- (cer) or citrine- (citr) tagged peripherin-2 or Rom-1 constructs as indicated. Binding curves were generated 
by plotting the FRET efficiency (EA) against the cer/citr molar ration (MR). The dots represent mean values of 1-7 
single FRET measurements ± SEM. The single EA values, EAmax, and numbers of independent measurements (n) 
for each combination are summarized in Supplementary Table 3. 
 
4.11 Subunit assembly of homo- and heteromeric perWT, perMT, and Rom-1
 complexes 
Sucrose density gradient centrifugation (SDGC) is a commonly used technique allowing the 
separation of covalently or non-covalently linked proteins across a sucrose gradient 
corresponding to their specific molecular weight. In previous studies, this method was already 
successfully applied to examine the impact of peripherin-2 mutants including perC214S on 
homomeric perMT-perMT or heteromeric perMT-Rom-1 interactions [28, 29, 77, 96]. However, 
due to the autosomal dominant fashion of PRPH2-linked adRP, many different combinations 
of peripherin-2 complexes can be formed in heterozygous patients: perWT-perWT, perMT-perMT, 
perWT-perMT, perWT-Rom-1, and perMT-Rom-1. Additionally, each of these combinations can 
exist in different equilibria of mono-, di-, and tetramers as well as higher-order oligomers. So 
far, this high complexity has prevented a more detailed investigation of how subunit assembly 
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might influence the rod OS targeting of the single peripherin-2 protein complexes. To examine 
the complexes that can be formed in heterozygous patients more systematically, a set of 
SDGC experiments was conducted with differentially tagged perWT, perMT, and Rom-1 
combinations transiently expressed in HEK293T cells. 
In good agreement with previous work [97], perWT was only detected in the fractions 
corresponding to the non-covalent tetramers and disulfide-linked octamers under non-reducing 
conditions (Figure 16A). In contrast, perP210L was predominantly found as monomer, non-
covalent dimer, and aggregates, but some complexes were also found as disulfide-linked 
tetramers and octamers (Figure 16B). perC214S exhibited a similar pattern as perP210L and was 
mainly detected as monomer, non-covalent dimer, and aggregates (Figure 16C). However, 
when co-expressed with perWT, the subunit assembly pattern of both mutants changed. perP210L 
was primarily found in the fractions containing monomers as well as non-covalent dimers, and 
a weak signal was also observed in the non-covalent tetramer fraction (Figure 16D). 
Interestingly, compared to perWT only, in presence of perP210L the pattern of perWT also slightly 
changed as a considerable amount of perWT appeared in the non-covalent dimer fraction 
(Figure 16D, cf. Figure 16A). As non-covalent dimers were virtually undetectable in the perWT 
only situation, this suggests that the corresponding fraction at least partially consists of perWT-
perP210L dimers. Co-expression of perWT with perC214S led to a substantial decrease in the 
formation of perC214S aggregates and mainly non-covalent dimers and monomers could be 
detected (Figure 16E). Moreover, unlike the perWT-perP210L combination, in presence of perWT 
perC214S could also be found in the non-covalently linked tetramer fractions. However, similar 
to the perWT-perP210L combination, when co-expressed with perC214S perWT signal was also 
detected in the non-covalent dimer fractions (Figure 16E). Considering that perWT alone 
virtually does not form any non-covalent dimers (cf. Figure 16A) and that perC214S alone does 
not form any non-covalent tetramers (cf. Figure 16C), it is most likely that these complexes 
consist of perWT-perC214S dimers and tetramers, respectively (Figure 16E).  
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Figure 16 SDGC experiments from different perWT, perMT, and Rom-1 combinations. (A-H) Shown are 
representative immunoblots (left panel) and the corresponding statistics (right panel) of each C-terminally myc- or 
flag-tagged combination as indicated. Each blot contains eleven fractions collected across the 5-20 % sucrose 
gradient. All fractions were normalized to the DNA standard mixed to the protein solution prior to SDGC as described 
in the materials and methods section 3.6. Fractions correlating to the DNA standard (975 kDa, 325 kDa, 130 kDa, 
and 49 kDa) are marked accordingly. The single peripherin-2 or Rom-1 complexes were found in following fractions: 
octamers, fraction 3-6; tetramers, fraction 6-8; dimers: fraction 9-10; monomers, fraction 10-11. Western blots were 
performed with antibodies recognizing either the myc-tag (first row of the left panel) or the flag-tag (second row of 
the left panel). For quantification (right panel), the percentage of total immunoreactivity related to the number of 
sinlge fractions for non-covalent or covalent complexes and aggregates was plotted against the eleven collected 
fractions. The fractions containing non-covalent dimers are highlighted by a dashed rectangle. The single values 
(percentages and numbers of independent experiments) for all combinations are summarized in Supplementary 
Table 4. 
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Following the analysis of the homomeric peripherin-2 combinations, the SDGC fractions of the 
heteromeric peripherin-2-Rom-1 complexes were examined. In accordance with previous 
reports [26, 97, 98], the co-expression of Rom-1 and perWT resulted in a robust Rom-1 signal 
detected in the non-covalent tetramer and covalently linked octamer fractions (Figure 16F). 
Additionally, Rom-1 was also found as non-covalent dimers and monomers. However, since 
virtually no perWT signal could be identified in these fractions, it is very likely that no  
perWT-Rom-1 heterodimers are present under these conditions (Figure 16F). After  
co-expressing Rom-1 with each mutant, both, perP210L and perC214S were almost exclusively 
found as non-covalent dimers and monomers (Figure 16G, H). Similar results were obtained 
for Rom-1 in the corresponding fractions. Unlike the Rom-1-perWT combination, in presence of 
perP210L and perC214S Rom-1 signal was almost exclusively detected in the dimer and monomer 
fractions indicating that Rom-1 predominantly forms heteromeric non-covalent dimers with 
both mutants (Figure 16G, H). Taken together, the results obtained from this SDGC analysis 
indicate that homomeric perWT-perMT and heteromeric perMT-Rom-1 complexes are primarily 
built of non-covalent dimers. 
 
4.12 Rod OS targeting of homo- and heteromeric perWT, perMT, and Rom-1 
 complexes 
The FRET (cf. chapter 4.10) and SDGC (cf. chapter 4.11) experiments from HEK293T cells 
indicate that perP210L and perC214S are in principle able to interact with perWT and Rom-1, albeit 
with markedly changed complex formation patterns. In this part of the study, it was assessed 
how the single complexes contribute to the protein transport/protein localization in the rod 
photoreceptors.  
Subretinal co-administration of two rAAVs encoding different transgenes yields very high  
co-transduction efficiencies in rods [89]. Based on this, rAAV-mediated gene delivery was used 
to (co-)express the different combinations of perWT, perMT, and Rom-1 in mouse rod 
photoreceptors. To distinguish between the different transgenes, perWT and Rom-1 were  
N-terminally fused to cerulean while perP210L and perC214S retained the citrine tag at their  
N-terminus. The rAAVs harboring the different peripherin-2 and Rom-1 constructs were 
subretinally injected into WT mice on P14. Four weeks post injection, the protein localization 
was examined on corresponding retinal slices from injected animals.  
Results 58 
 
Figure 17 Rod OS targeting of perMT and perWT-perMT complexes. (A-D) Immunohistology of retinas injected 
with citrine-tagged mutants (perP210L, A, and perC214S, B), or co-injected with the respective mutants and  
N-terminally cerulean-tagged perWT (cer-perWT, C-D). B1a (red) was used as rod OS marker. Scale bar represents 
30 µm. 
 
Similar to the results shown in Figure 12A and 12B in chapter 4.6, both mutants were retained 
in the inner segments when expressed alone (Figure 17A, B). However, simultaneous co-
administration of titer-matched perWT and perMT resulted in a substantial rescue of rod OS 
targeting for perP210L and perC214S (Figure 17C, D). Additionally, co-expression of perWT also 
rescued the vesicular-like expression pattern of perP210L in the rod inner segments (Figure 17C) 
and increased the expression of perC214S protein (Figure 17D).  
To investigate whether similar rescue effects could be achieved in the presence of Rom-1, 
transgenic Rom-1 and peripherin-2 constructs were co-delivered to murine rods (Figure 18).  
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Figure 18 Rod OS targeting of Rom-1-perWT/MT complexes. Immunohistology of retinas co-injected with  
N-terminally cerluean-tagged Rom-1 (cer-Rom-1) and citr-perWT (A), citr-perP210L (B), and citr-perC214S (C). B1a (red) 
was used as rod OS marker. Scale bar represents 30 µm. 
 
After co-administration of Rom-1 and perWT, both proteins were exclusively detected in rod 
OSs (Figure 18A). However, in contrast to perWT, Rom-1 could not noticeably rescue the perMT 
OS targeting (Figure 18B and C). Nevertheless, a significant portion of transgenic Rom-1, most 
likely the Rom-1-perMT heterodimers, was withheld in the rod ISs (Figure 18B, C).  
In summary, the co-administration of transgenic perWT rescued the OS targeting of perP210L and 
perC214S in rod photoreceptors. Conversely, co-delivery of transgenic Rom-1 with perP210L or 
perC214S led to a partial retention of Rom-1 in the rod ISs. These findings in combination with 
the results obtained from the SDGC experiments strongly indicate that perWT-perMT, but not 
perMT-Rom-1 heterodimers can be efficiently targeted to rod OSs. 
 
4.13 Analysis of the perWT-perMT binding properties in rod OSs using FRET 
The results obtained from the co-IP and FRET experiments performed in HEK293T cells  
(cf. chapter 4.8 and 4.10) revealed that both peripherin-2 mutants display a reduced binding 
to perWT. This finding can be explained by a decreased binding affinity of the perWT-perMT 
interaction and/or decreased initial binding kinetics of both mutants to perWT. However, as seen 
in the SDGC experiments, in HEK293T cells transiently co-transfected with perWT and perMT, 
in addition to the perWT-perMT complexes, each mutant can also exist as monomers or can 
undergo self-interaction forming dimers and aggregates (cf. Figure 16B-E). Considering that 
all these combinations would contribute to the overall FRET signal, the reduction of EAmax in 
HEK293T cells does not allow discriminating between the mechanisms described above. 
However, the fact that rod OS targeting of both mutants is rescued upon co-delivery of perWT 
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provides an opportunity to address this issue directly: In contrast to HEK293T cells, each of 
the mutant proteins found in rod OSs must be arranged in complexes with perWT. This 
happenstance allows for drawing direct conclusions about the perWT-perMT binding 
characteristics under close-to-native conditions by performing FRET measurements on 
isolated “rescued” rod OSs. For this purpose, WT mice were subretinally co-injected on P14 
with rAAVs containing the respective perWT and perMT FRET pairs. Four weeks post injection, 
rod OSs were isolated and FRET measurements were performed on single transduced OSs 
simultaneously expressing cerulean-tagged perWT and citrine-tagged perMT (Figure 19). 
 
 
Figure 19 FRET experiments from rod OSs of retinas co-injected with perWT and perMT rAAVs. (A-C) 
Representative confocal images of FRET channels showing a single rod OS co-expressing cer-perWT and  
citr-perWT (A), cer-perWT and citr-perP210L (B), or cer-perWT and citr-perC214S (C). Scale bar represents 2 µm. (D-F) 
Binding curves obtained from the corresponding FRET measurements of the different combinations displayed in 
(A-C). The dots represent mean values of 1-7 single FRET measurements ± SEM. The single EA values, EAmax, and 
numbers of independent measurements (n) for each combination are summarized in Supplementary Table 3. 
 
For all three combinations (cer-perWT+ citr-perWT, cer-perWT + citr-perP210L, and cer-perWT + citr-
perC214S), robust FRET signals could be measured. Moreover, as the cer/citr MR distinctively 
varied among the single rod OSs, the calculation of binding curves was possible. Strikingly, 
the EAmax values from the isolated rod OSs strongly differed from the FRET results obtained 
from HEK293T cells (cf. Figure 15D, E). EAmax was either increased for the perWT-perP210L FRET 
pair or very close to that of the perWT only interaction in case of the perWT-perC214S combination 
(Figure 19D-E, Supplementary Table 3). These results suggest that the robust decrease in the 
perWT-perMT interaction observed in FRET and co-IP experiments (cf. Figure 14 and 15) in 
HEK293T cells most likely results from a decrease in the initial binding kinetics of both mutants 
to perWT. 
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5 Discussion 
This study unveiled several molecular mechanisms regarding the differential impact of rod- 
and cone-dominant PRPH2 mutations in the respective photoreceptor type. 
In the first part of the study, the rAAV-mediated expression of perWT and perMT minigenes in 
murine photoreceptors uncovered a novel role of mRNA splicing in peripherin-2 
pathophysiology in rods and cones. Minigene-derived perWT and perMT transcripts yielded three 
distinct isoforms in rods and cones: 1) the correctly spliced, 2) the intron 1 retention, and 3) 
the unspliced peripherin-2. Importantly, the existence of correctly spliced and unspliced 
transcripts was confirmed by qPCR from native human and murine retina as well as in  
FAC-sorted murine rods and cones. Furthermore, the relative amounts of the two isoforms 
obtained from the rAAV-mediated expression of PRPH2 minigenes correlated with those from 
sorted photoreceptors. In FAC-sorted rods, the amount of correctly spliced transcript by far 
exceeded the amount of unspliced peripherin-2. In contrast, FAC-sorted cones displayed a 
considerably higher amount of unspliced transcript relative to the correctly spliced variant. 
These findings indicate that the splicing machinery is somewhat different in rods and cones. It 
remains unclear why the two photoreceptor types require differential mRNA splicing of PRPH2. 
As only the correctly spliced isoform is translated into protein (cf. chapter 4.5), low levels of 
this transcript in cones might have evolved to keep peripherin-2 expression rather low in this 
cell type. Previous studies could demonstrate that peripherin-2 is required for rod and cone 
OS morphogenesis. Rods from peripherin-2 deficient mice do not show OS-like structures, 
whereas cones develop atypical OSs [18, 20, 99-101]. Given these findings, the divergent 
peripherin-2 expression levels in rods and cones might also be relevant for the differential OS 
structure development in these cells. However, additional studies are necessary to reveal the 
exact function of differential peripherin-2 expression in photoreceptors. 
 
A comparison of the splicing pattern and protein expression of the perMT in rods and cones 
uncovered a novel genotype-phenotype correlation (Table 5). Three out of the five perMT linked 
to cone defects led to a strong increase of correctly spliced peripherin-2 compared to perWT. 
Accordingly, this increased mRNA splicing efficiency yielded elevated protein expression 
levels as observed in immunostainings and western blotting of transduced retinas. None of the 
cone-dominant perMT impaired cone OS localization or affected the protein expression pattern. 
A previous study demonstrated that a moderate overexpression of peripherin-2 in cones 
(approx. 50 %) does not affect their morphology or function [102]. However, the results of this 
study indicate that peripherin-2 point mutations could result in protein levels far beyond of the 
50 % overexpression analyzed in the aforementioned study, which in turn might very well have 
negative impacts on cones. The remaining two of the five analyzed cone-dominant perMT, 
Discussion 62 
perS212T and perR220W, did not exhibit any effects on mRNA splicing or protein expression. This 
indicates that increased protein expression is not a general mechanism solely explaining the 
penetrance of all cone disease-linked perMT. This is in line with a previous study that analyzed 
perR172W, another cone-specific mutation located in the D2 loop of peripherin-2. This mutant 
led to cone degeneration in mice without affecting the protein expression [103]. Additional 
studies need to be performed to identify whether protein overexpression, functional defects 
caused by the perMT, or both mechanisms contribute to the disease phenotype. 
 
Table 5 Summary of the effects caused by the single mutants analyzed in this study. 
 rods cones 
 C214S P210L S198R Q226E W246R G249S V209I R195L R220Q S212T R220W 
Protein 
expression 
   
n.c. n.c. 
    
n.c. n.c. 
Protein 
localization 
IS IS OS OS OS OS OS OS OS OS OS 
mRNA 
splicing 
n.c. n.c. n.c. n.c. n.c. 
novel 
donor 
splice site 
increased 
splice 
efficiency 
increased 
splice 
efficiency 
increased 
splice 
efficiency 
n.c. n.c. 
   , increase,    , decrease in protein expression compared to the WT.  
IS, inner segment.  
OS, outer segment. 
n.c., no change. 
 
 
In comparison to perMT linked to cone diseases, four out of the six perMT associated with adRP 
(perS198R, perP210L, perC214S, and perG249S) affected the protein expression via one of three 
distinct mechanisms: protein degradation, protein mislocalization and altered mRNA splicing 
(Table 5). Despite their diversity, these mechanisms collectively result in decreased protein 
expression levels in rods. 
Among these, perG249S was the only mutant that affected mRNA splicing. This mutant gave rise 
to an additional fourth splice isoform due to the generation of a novel donor splice site within 
exon 2 (cf. Figure 7B). Except for correctly spliced peripherin-2, all other splice variants 
detected in this study including this new isoform seemed to be degraded on the mRNA level, 
most of them probably due to the NMD mechanism. Nevertheless, this aberrantly spliced 
isoform led to a decrease in the relative amount of the correctly spliced transcript for perG249S 
by approx. 20 %. A previous study using transgenic mice showed that the critical level of 
peripherin-2 expression required for maintaining proper morphology and function of rods is 
about 80 % of the native peripherin-2 expression [102]. This suggests that the 20 % reduction 
of protein expression caused by perG249S is very close to this critical level and might be sufficient 
to cause retinal degeneration in the affected patient.  
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The perS198R mutant appeared to be prone to degradation as it gave rise to an intense additional 
band in the western blot performed on transduced retinas (cf. Figure 12). Such degradation 
could be due to improper protein folding resulting in the exposure and/or the masking of 
existing native protease cleavage sites. The protease cleavage assay performed on 
membrane preparations from transfected HEK293T cells did not reveal any changes in the 
protein structure of this mutant (cf. Figure 14D). However, it is conceivable that in the native 
context other factors contribute to the degradation of perS198R resulting in its strongly reduced 
protein expression in rods.  
 
The remaining two mutants that led to a reduction of protein expression in rods were adRP-
linked perC214S and perP210L. Among all mutants analyzed in this study, only these two were 
mislocalized to the ISs of rod photoreceptors (cf. Figure 11 and Figure 12). In line with the 
aforementioned dose-dependency, transgenic mice expressing perC214S also exhibited 
reduced levels of mutant protein in rod OSs resulting in haploinsufficiency [77]. Interestingly, 
genetic supplementation of perWT on the perC214 mutant background by generating double 
transgenic mice resulted in a noticeable rescue of the retinal function [78]. Although helpful in 
initial stages of therapy development, genetic supplementation is restricted to model 
organisms. In contrast, rAAV-mediated gene delivery has proven to be a very promising 
approach for a therapeutic intervention in retinal diseases like RP in mammals [52, 104-106]. 
Using a rAAV-based approach, this study shows for the first time that rod OS targeting of perMT 
can be rescued in vivo upon simultaneous co-delivery of perWT (Figure 17). The  
co-supplementation of perWT led to the rescue of protein expression and protein localization of 
both, perC214S and perP210L. This finding helps deepening the understanding of PRPH2-linked 
disease mechanisms in photoreceptors and could support the development of future gene 
therapies for patients with mislocalizing peripherin-2 mutants. However, it remains unclear 
whether the rescue of perMT rod OS targeting caused by the delivery of perWT has any 
detrimental effects in patients heterozygous for these mutations. Consequently, prior to gene 
therapy, the long-term effects of the mutant rescue on retinal degeneration need to be 
evaluated in appropriate animal models. 
 
WT mice transduced with the single transgenic perWT or perMT constructs also express 
peripherin-2 endogenously. Apparently, as perC214S and perP210L were completely mislocalized 
in the absence of transgenic perWT, endogenous peripherin-2 is insufficient to rescue protein 
localization. In line with this, in a recent study using heterozygous transgenic knock-in mice 
expressing perC214S, this mutant also remained in the ISs and was highly prone to degradation 
[77]. Hence, rAAV-mediated delivery of perC214S to WT mice leads to effects comparable to 
those obtained from mice heterozygous for this mutant. The fact that perC214S mutant protein is 
not targeted to rod OSs indicates that under these conditions perWT-perC214S complexes are 
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most likely not formed in considerable amounts. However, additional rAAV-mediated 
supplementation of perWT very likely exceeds the critical levels necessary for efficient perWT-
perC214S complex formation. This further emphasizes the highly critical role of peripherin-2 
dosage in the pathophysiology of photoreceptors.  
 
This study also provides novel insights into the structural impacts of perC214S and perP210L on 
peripherin-2 folding. Both mutants rearrange the distal part of the D2 loop with the affected 
region being located around the aa position 260 (cf. Figure 14). The perC214S and perP210L 
mutants may also structurally rearrange other parts of this domain which could not be covered 
by the protease cleavage assay performed in this study. However, based on this assay it is 
very unlikely that they lead to folding changes in the proximal part of the D2 loop around the 
highly conserved tetraspanin CCG motif.  
Furthermore, perC214S and perP210L affect residues that are located within the PxxCC motif, 
which is conserved among tetraspanins [90]. Previous studies demonstrated that both cysteine 
residues (C213 and C214) of this motif are crucial for the formation of intramolecular disulfide 
bonds [29, 107], whereas the role of the proline residue (P210) remained unknown. This study 
shows that the PxxCC motif and its flanking regions (6-9 aa) are not involved in homomeric 
peripherin-2 interactions. However, the P210 and C214 residues appear to be critical for the 
proper folding of the D2 loop as no other mutants in close proximity to these positions (e.g. 
perV209I or perS212T) changed the accessibility of the protease cleavage site in this part of 
peripherin-2. 
In addition, perC214S and perP210L show reduced binding to perWT and its interaction partner  
Rom-1 in co-IP and FRET experiments performed in HEK293T cells (cf. Figure 14 and Figure 
15). The results of this study indicate that this reduction is based on the misfolding of the D2 
loop induced by the two mutants. It is conceivable that this structural change might decrease 
the affinity of the perMT to bind to perWT and Rom-1. However, the FRET measurements from 
isolated rod OSs uncovered that reduced initial binding kinetics of perC214S and perP210L rather 
than decreased binding affinities are most likely causative for the decreased interaction with 
perWT (cf. Figure 19). This suggests that the mutant misfolding interferes with the initial binding 
of perMT to perWT, but once bound, there is hardly any change in their affinity to perWT. These 
findings are also in line with the results from the peptide competition assay suggesting that the 
PxxCC motif is not part of the interface for homomeric peripherin-2 interactions.  
 
SDGC experiments performed to analyze the effects of perC214S and perP210L on protein subunit 
assembly revealed that in the presence of perWT they just form considerably low amounts of 
tetramers (cf. Figure 16). Instead, both mutants preferentially formed dimers with perWT and 
Rom-1. However, only non-covalent transgenic perWT-perMT and no perMT-Rom-1 heterodimers 
could be transported to rod OSs (Figure 20). This finding is very surprising for two reasons: 
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First, non-covalent peripherin-2 tetramerization has been postulated to be crucial for rod OS 
targeting [28]. However, this conclusion was indirectly drawn from two findings:  
1) Tetramerization-deficient peripherin-2 mutants could not be trafficked to rod OSs [28].  
2) No dimers among perWT complexes isolated from rod OSs could be detect [98]. These 
experiments, however, are insufficient to state whether perWT-perWT or perWT-perMT dimers can 
in principle be targeted to rod OSs. This study for the first time demonstrates that perWT-perMT 
dimers can be transported to rod OSs.  
The second surprising finding of this part of the study is that, in contrast to perWT,  
rAAV-mediated co-delivery of Rom-1 and the corresponding increase in Rom-1 levels did not 
result in any rescue of perC214S or perP210L. This indicates that Rom-1 is not able to fully 
compensate for the function of peripherin-2 in rod photoreceptors. So far, one can only 
speculate about the physiological role of these opposing effects of peripherin-2 and Rom-1 in 
terms of binding and trafficking misfolded perMT.  
 
 
 
Figure 20 Rod OS targeting of perMT homo- and heteromeric dimeric complexes. The localization of the 
different complexes (perWT-perMT, Rom-1-perMT, and perMT only) in the rod photoreceptors is indicated by a dashed 
gray rectangle. The position of the D2 loop is highlighted in red and perMT induced misfolding is highlighted via an 
incision. perWT/MT, blue; Rom-1, green. 
 
In the SGDC experiments (cf. Figure 16), the presence of Rom-1 entirely prevented the 
formation of perMT aggregates and shifted their complex composition almost completely 
towards perMT-Rom-1 heterodimers. As these heterodimers were not targeted to rod OSs, it is 
conceivable that Rom-1 could be acting as a kind of gate keeper preventing the transport of 
incorrectly folded peripherin-2 mutants to the OSs. Previous studies have shown that digenic 
RP-linked ROM1 mutations prevent the forming of peripherin-2 homotetramers and higher-
order oligomers [44, 108]. In combination with the results of this study, this indicates that Rom-
1 might play an important role in fine-tuning the ratio of peripherin-2/peripherin-2 and 
peripherin-2/Rom-1 complexes [36].  
 
This study provides a novel experimental design allowing a more accurate analysis of disease 
mechanisms of point mutations in photoreceptors. Typically, studies focusing on the functional 
consequences of exonic point mutations are utilizing the full coding sequence  
(or just single exons) of the respective gene lacking any intronic sequences [109-111]. Here, 
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by means of PRPH2 minigenes containing the full coding sequence and the flanking intronic 
regions, additional disease mechanisms were identified which cannot be found using the 
classical coding-sequence-only approach. These results strongly suggest that, whenever 
possible, analysis of disease-associated exonic point mutations should be performed on 
minigenes.  
The disease mechanisms of PRPH2 mutants identified in this study include the effects on 
mRNA splicing, protein expression, protein targeting/localization, and protein-protein 
interactions. The majority of perMT linked to cone diseases lead to an upregulated  
peripherin-2 expression in cones by increasing the mRNA splicing efficiency. In contrast, the 
majority of perMT associated with rod disorders results in a downregulation of peripherin-2 
expression in rods via different mechanisms including aberrant mRNA splicing. It remains 
unclear why rod defects correlate with lowered amounts of peripherin-2 whereas cones seem 
to be susceptible to a high expression of this protein. Nevertheless, the latter finding suggests 
that strong overexpression of PRPH2 in cones should be avoided in future gene therapy 
approaches. Finally, the results from the second part of this study indicate that  
Rom-1 might act as a molecular gate keeper preventing misfolded peripherin-2 from being 
transported to rod OSs. This raises the possibility that the efficiency of gene supplementation 
therapy of PRPH2-linked RP could be improved by co-delivering peripherin-2 and Rom-1.  
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6 Summary 
The tetraspanin peripherin-2 is a transmembrane protein regulating the development, 
maintenance and renewal of the light-sensing compartments of photoreceptors termed outer 
segments (OSs). Mutations in the human peripherin-2 gene (PRPH2) are associated with 
severe retinal dystrophies leading to the degeneration or dysfunction of rods or cones. The 
molecular pathways underpinning this differential penetrance of the mutants in both 
photoreceptor types are largely unknown. The initial hypothesis of this study was that the rod- 
or cone-dominance of the PRPH2 mutants correlates with their differential effects on mRNA 
splicing, protein expression, protein transport and/or protein-protein interaction in these cells. 
To address this issue, six rod- and five cone-dominant exonic PRPH2 point mutations were 
analyzed in cell culture and in transduced photoreceptors. 
In the first part of this study, the impacts of the PRPH2 mutations on mRNA splicing and 
concomitant protein expression were investigated in rods and cones. For this purpose, wild 
type (perWT) and mutant (perMT) human PRPH2 minigenes were expressed in murine 
photoreceptors using recombinant adeno-associated virus (rAAV)-mediated gene delivery. 
Three different PRPH2 splice isoforms were found in rods and cones: 1) Correctly spliced  
2) Intron 1 retention 3) Unspliced. Among these, only the correctly spliced transcript resulted 
in detectable protein expression. Surprisingly, differential splicing of PRPH2 led to high levels 
of the correctly spliced isoform in rods and to low levels in cones. Three out of the five  
cone-dominant perMT considerably enhanced correct splicing of PRPH2, which correlated with 
a strongly elevated mutant protein expression in these cells. In contrast, four out of the six rod-
dominant perMT resulted in reduced protein expression via different pathways including 
aberrant mRNA splicing, protein degradation, and protein mislocalization. These findings 
unveil novel disease mechanisms of PRPH2 mutations in photoreceptors and identify the 
molecular determinants underlying the differential penetrance of rod- and cone-dominant 
mutations in these cells. Furthermore, these results suggest differential strategies for the 
treatment of rod- and cone-dominant PRPH2 mutations.  
Peripherin-2 forms homomeric peripherin-2/peripherin-2 and heteromeric complexes with its 
homolog Rom-1. The contribution of these complexes and the specific role of Rom-1 in the 
pathophysiology of PRPH2 mutations remained unclear so far. In the second part of this study, 
the impact of the aforementioned PRPH2 mutations on homo- and heteromeric peripherin-2 
protein assembly was addressed. Two rod-dominant mutations (perP210L and perC214S) largely 
prevented the core peripherin-2/peripherin-2 and peripherin-2/Rom-1 tetramerization resulting 
predominantly in dimer formation. Surprisingly, however, in contrast to their perWT/perMT 
counterparts, the perMT/Rom-1 dimers could not be properly targeted to the OSs. This finding 
Summary 68 
uncovered unexpected opposing roles of perWT and Rom-1 in OS targeting of rod-dominant 
peripherin-2 mutations suggesting novel treatment strategies for the affected patients.  
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7 Zusammenfassung 
Das Tetraspanin Peripherin-2 ist ein Transmembranprotein, das die Entwicklung, 
Aufrechterhaltung und Erneuerung der Licht-sensitiven Kompartimente von Photorezeptoren, 
der sogenannten Außensegmente, reguliert. Mutationen im humanen Peripherin-2 Gen 
(PRPH2) sind mit schweren retinalen Erkrankungen assoziiert, die zur Degeneration oder dem 
Funktionsverlust von Stäbchen oder Zapfen führen. Die molekularen Ursachen, die zu dieser 
differenziellen Ausprägung der Mutationen in Stäbchen und Zapfen führen, sind weitestgehend 
unbekannt. Die Ausgangshypothese dieser Studie war, dass die Stäbchen- bzw. 
Zapfendominanz der PRPH2 Mutationen mit deren Auswirkungen auf mRNA Spleißen, 
Proteinexpression, -transport oder Protein-Protein-Interaktionen zusammenhängt. Um diese 
Fragestellung zu adressieren, wurden sechs Stäbchen- und fünf Zapfen-spezifische exonische 
PRPH2 Punktmutationen in Zellkulturexperimenten und in transduzierten Photorezeptoren 
analysiert. 
Im ersten Teil dieser Studie wurden die Effekte von PRPH2 Mutationen auf das mRNA 
Spleißen und die daraus resultierende Proteinexpression in Stäbchen und Zapfen untersucht. 
Zu diesem Zweck wurden wildtypische (perWT) und mutierte (perMT) humane PRPH2 Minigene 
mittels rekombinantem Adeno-assoziiertem Virus (rAAV)-vermittelten Gentransfers in murinen 
Photorezeptoren exprimiert. Drei verschiedene PRPH2 Spleißisoformen wurden in Stäbchen 
und Zapfen vorgefunden: 1) Korrekt gespleißt 2) Intron 1 Retention 3) Ungespleißt. Von diesen 
Isoformen führte nur das korrekt gespleißte Transkript zu einer detektierbaren 
Proteinexpression. Überraschenderweise führte das differenzielle Spleißen von PRPH2 in 
Stäbchen zu großen Mengen an korrekt gespleißter Isoform und zu vergleichsweise sehr 
geringen Mengen dieses Transkripts in Zapfen. Drei der fünf Zapfen-spezifischen perMT 
steigerten deutlich den Anteil an korrekt gespleißter PRPH2 mRNA, was mit einer stark 
erhöhten Expression an mutiertem Protein in diesen Zellen einherging. Im Gegensatz hierzu 
resultierten vier der sechs Stäbchen-spezifischen perMT aufgrund verschiedener Mechanismen 
wie aberrantem mRNA-Spleißen, Proteindegradierung und Proteinfehllokalisation in einer 
verminderten Proteinexpression. Durch diese Erkenntnisse werden neue 
Krankheitsmechanismen aufgezeigt, die PRPH2 Mutationen zu Grunde liegen, und legen die 
molekularen Mechanismen dar, die zur differenziellen Penetranz in Stäbchen und Zapfen 
führen können. Gleichzeitig deuten diese Ergebnisse darauf hin, dass zur Therapie Stäbchen- 
und Zapfen-dominanter PRPH2 Mutationen unterschiedliche Strategien angewendet werden 
müssten.  
Peripherin-2 kann homomere Peripherin-2/Peripherin-2 und heteromere Komplexe mit seinem 
Homolog Rom-1 formen. Der genaue Beitrag dieser Komplexe und die spezifische Rolle von 
Rom-1 in der RP-Pathophysiologie von PRPH2 Mutationen blieben bisher weitestgehend 
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ungeklärt. Im zweiten Teil dieser Studie wurde der Einfluss der zuvor genannten PRPH2 
Mutationen auf die Homo- und Heteromerbildung von Peripherin-2 untersucht. Zwei Stäbchen-
spezifische Mutationen (perP210L und perC214S) verhinderten größtenteils die zentrale 
Peripherin-2/Peripherin-2 und Peripherin-2/Rom-1 Tetramerisierung und formten stattdessen 
präferentiell Dimere. Überraschenderweise konnten jedoch die perMT-Rom-1 Dimere, im 
Gegensatz zu ihren perWT-perMT Gegenstücken, nicht korrekt in die Außensegmente 
transportiert werden. Diese Erkenntnis deckt unerwartete gegensätzliche Rollen von perWT und 
Rom-1 beim Transport von Stäbchen-spezifischen Peripherin-2 Mutationen in die 
Außensegmente auf. Dies bietet die Grundlage zur Entwicklung neuer Therapieansätze für 
Patienten, die von Mutationen in PRPH2 betroffen sind. 
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9  Appendix 
9.1 Supplementary tables 
Supplementary Table 1 In silico splice analysis of 30 point mutations in exon 2 of peripherin-2. All changes 
for single splice elements or donor and acceptor sites predicted by the ASSEDA software are shown as fold changes 
to the WT. For NNSplice based prediction, single scores are given for perWT and changes to this score for the 
mutants are highlighted in blue.    or    , increase or decrease of the score for a given recognition sequence or for a 
donor and acceptor site, respectively. The numbers next to the arrows indicate the fold changes to the WT. AS, 
acceptor splice site; DS, donor splice site; n.c., no change. The position of the respective AS or DS  
(AG or GT) within the given DNA sequence is shown in red. SF2_ASF, SC35, SRp40, and SRp55, serine/arginine 
(SR)-rich proteins belonging to the exonic splice enhancers (ESEs). hnRNPA1, proteins belonging to the exonic 
splice silencers (ESSs). Both, the abolition of the consensus sequence of ESEs as well as the generation of a novel 
recognition sequence for ESSs might lead to exon skipping or intron retention. The mutations analyzed in this study 
are underlined. 
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Supplementary Table 2 Relative intensity percentages of peripherin-2 isoforms obtained for perWT and perMT 
minigenes (cf. Figure 7). MV, mean value; SEM, standard error of the mean; n.s., not significant. 
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Supplementary Table 3 FRET measurements from HEK293T cells and isolated rescued rod Oss (cf. Figure 
15 and Figure 19). n, number of cells/rod OSs. 
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Supplementary Table 4 Quantification of the SDGC experiments. Values are given as mean values ± SEM. 
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Supplementary Table 5 Primers used for cloning of the human peripherin-2 minigene. 
Primer name Sequence 5’ – 3’ 
hPrph2_BamHI_F CCGGATCCGCCACCATGGCGCTACTGAAAGTCAAGT 
hPrph2_NotI_R GATCGCGGCCGCTCAGCCAGCCTCTGGGGCCTGG 
OL_Prph2_In1_F CCTCTTTGACCCATAAAAAATCGAGGAAGGCAGGGGCATTTA 
OL_Prph2_In1_R TAAATGCCCCTGCCTTCCTCGATTTTTTATGGGTCAAAGAGG 
OL_Prph2_In2_F GGCCTCCACCTTTTGTATTTAGACATGAGGCTGGAGAAGAGT 
OL_Prph2_In2_R ACTCTTCTCCAGCCTCATGTCTAAATACAAAAGGTGGAGGCC 
 
Supplementary Table 6 Primers used for the introduction of the single point mutations in the human 
peripherin-2 minigene using side-directed mutagenesis. The base pair required for the amino acid exchange is 
highlighted in red. 
Primer name Sequence 5’ – 3’ 
hPrph2_R195L_F TGTTTCCCTTTAAGTCTAATCAAGAGCAACGTG 
hPrph2_R195L_R CACGTTGCTCTTGATTAGACTTAAAGGGAAACA 
hPrph2_S198R_F TAAGTCGAATCAAGAGGAACGTGGATGGGCGGT 
hPrph2_S198R_R ACCGCCCATCCACGTTCCTCTTGATTCGACTTA 
hPrph2_V209I_F GTACCTGGTGGACGGCATCCCTTTCAGCTGCTG 
hPrph2_V209I_R CAGCAGCTGAAAGGGATGCCGTCCACCAGGTAC 
hPrph2_P210L_F CTGGTGGACGGCGTCCTTTTCAGCTGCTGCAAT 
hPrph2_P210L_R ATTGCAGCAGCTGAAAAGGACGCCGTCCACCAG 
hPrph2_S212T_F GACGGCGTCCCTTTCACCTGCTGCAATCCTAGC 
hPrph2_S212T_R GCTAGGATTGCAGCAGGTGAAAGGGACGCCGTC 
hPrph2_C214S_F GTCCCTTTCAGCTGCTCCAATCCTAGCTCGCCA 
hPrph2_C214S_R TGGCGAGCTAGGATTGGAGCAGCTGAAAGGGAC 
hPrph2_R220Q_F AATCCTAGCTCGCCACAGCCCTGCATCCAGTAT 
hPrph2_R220Q_R ATACTGGATGCAGGGCTGTGGCGAGCTAGGATT 
hPrph2_R220W_F CAATCCTAGCTCGCCATGGCCCTGCATCCAGTA 
hPrph2_R220W_R TACTGGATGCAGGGCCATGGCGAGCTAGGATTG 
hPrph2_Q226E_F GCCCTGCATCCAGTATGAGATCACCAACAACTC 
hPrph2_Q226E_R GAGTTGTTGGTGATCTCATACTGGATGCAGGGC 
hPrph2_W246R_F GGAGGAGCTCAACCTGCGGGTGCGTGGCTGCAG 
hPrph2_W246R_R CTGCAGCCACGCACCCGCAGGTTGAGCTCCTCC 
hPrph2_G249S_F CAACCTGTGGGTGCGTAGCTGCAGGGCTGCCCT 
hPrph2_G249S_R AGGGCAGCCCTGCAGCTACGCACCCACAGGTTG 
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Supplementary Table 7 Primers used for the amplification of the splice isoforms resulting from the 
peripherin-2 minigenes (cf. Figure 7B). 
Primer name Sequence 5’ – 3’ 
Citr_End_Seq_F GGCATGGACGAGCTATACAAG 
hPrph2_E3_Seq_R GGTTGGACACACCATCCAGCG 
 
Supplementary Table 8 Primers used for the detection of native murine (mP) and human (hP) peripherin-2 
transcripts via qPCR (cf. Figure 9). cs, correctly spliced; us, unspliced. 
Primer name Sequence 5’ – 3’ 
Alas fwd TCGCCGATGCCCATTCTTATC 
Alas rev GGCCCCAACTTCCATCATCT 
Rhodopsin fwd GCCTCGAGAGCCGCAGCCATG 
Rhodopsin rev GCAGGAACATGTACGCTGCC 
M-opsin fwd GTTCCAGAGACAGTTTTCTAC 
M-opsin rev CAACGACCACAAGAATCATCC 
mP-cs_F TCTCCTCCAAGGAGGTCAAAG 
mP-cs_R GAGTCCGGCAGTGATGCTCAC 
mP-us_F GGGAGGATCTGCTGCTTGGTG 
mP-us_R GCTCACCAGGTCTGTCTTCAC 
ALAS fwd GATGTCAGCCACCTCAGAGAAC 
ALAS rev CATCCACGAAGGTGATTGCTCC 
hP-cs_F GTGGATCAGCAATCGCTACC 
hP-cs_R GGTTGGACACACCATCCAGCG 
hP-us_F GAAGTGGCCCCTGTTGAGAAG 
hP-us_R CATTAGACCCAAATGGGACCG 
 
Supplementary Table 9 Primers used for cloning of truncated peripherin-2 (cf. Figure 10).  
Primer name Sequence 5’ – 3’ 
hPrph2_trunc_F CAGCAGCCTCATGAATTCCTAGGGCGTCGTCACACTTCTCG 
hPrph2_trunc_R CGAGAAGTGTGACGACGCCCTAGGAATTCATGAGGCTGCTG 
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9.2 Abbreviations 
aa amino acid 
adRP autosomal dominant retinitis pigmentosa 
AFVD adult-onset foveomacular vitelliform dystrophy 
Alas aminolevulinic acid synthase 
APS ammonium persulfate 
2x BBS 2x BES buffered saline 
BES N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid 
bp base pair 
CaCl2 calcium chloride 
cap genes for adeno viral packaging 
cDNA complementary DNA 
cm centimeter 
CNGB1a cyclic nucleotide gated channel beta 1a 
CO2 carbon dioxide 
co-IP co-immunoprecipitation 
CRISPR clustered regularly interspaced short palindromic repeats 
CT cycle threshold 
dk donkey 
DNA deoxyribonucleic acid 
H2O water 
DTT dithiothreitol 
EAmax maximal FRET efficiency 
E. coli Escherichia coli 
EDTA ethylenediaminetetraacetic acid 
EGFP enhanced green fluorescent protein 
FACS fluorescence-activated cell sorting 
FBS fetal bovine serum 
FRET Förster resonance energy transfer 
g gram 
g gravity 
GCL ganglion cell layer 
gt goat 
h hour 
HCl hydrochloric acid 
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HEK293T human embryonic kidney cells expressing the SV40 large T antigen 
HRP horseradish peroxidase 
hRHO human rhodopsin promoter 
INL inner nuclear layer 
IPL inner plexiform layer 
IS inner segment 
ITR inverted terminal repeat 
IRD inherited retinal disease 
kb kilobase pair 
KCl potassium chloride 
l liter 
M molar 
MgCl2 magnesium chloride 
µg microgram 
µl microliter 
mg milligram 
min minute 
mM millimolar 
ml milliliter 
MOPS 3-morpholinopropane-1-sulfonic acid 
mRNA  messenger RNA 
mSws murine short wavelength opsin promoter 
MW molecular weight 
NaCl sodium chloride 
ng nanogram 
nm nanometer 
NMD nonsense-mediated mRNA decay 
ONL outer nuclear layer 
OPL outer plexiform layer 
OS outer segment 
pAD Helper adenovirus helper plasmid 
PAGE polyacrylamide gel electrophoresis 
PB phosphate buffer 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
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PFA paraformaldehyde 
PMMA polymethyl methacrylate 
Prph2/PRPH2 peripherin-2 
PVDF polyvinylidene fluoride 
qPCR quantitative real-time PCR 
rAAV recombinant adeno-associated virus 
rb rabbit 
rep genes for adeno viral replication 
rds/RDS retinal degeneration slow 
RNA ribonucleic acid 
Rom-1 rod outer segment membrane protein 1 
RPE retinal pigment epithelium 
rpm revolutions per minute 
RT room temperature 
RT-PCR reverse transcription PCR 
SDS sodium dodecylsulfate 
sec second 
SEM standard error of the mean 
SDGC sucrose density gradient centrifugation 
SV40 simian virus 
T1-T4 transmembrane domain 1-4 
TBE tris-borate EDTA 
TBST tris-buffered saline with Tween20 
TEMED tetramethylethylenediamine 
TRIS tris(hydroxymethyl)aminomethane 
WPRE woodchuck hepatitis virus posttranscriptional regulatory element 
WT wild type 
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